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The aims of this study were to 1) describe endocrine therapy (ET) non-initiation, 
non-adherence, and duration by age, race, and temporal trend; 2) identify demographic, 
clinical, and pharmaceutical factors that are associated with an individual’s ET usage; 
and 3) understand from the survivor perspective which modifiable factors could have the 
greatest impact on the likelihood of ET continuation. 
This study utilized a convergent parallel mixed methods design. The sample 
included female South Carolina (SC) residents ages 18-64 at diagnosis with hormone 
receptor-positive breast cancer. SC Central Cancer Registry incidence data linked with 
South Carolina Medicaid data (N=3,830) were along with focus groups in four SC 
locations (N=22). Age, race, relative risk and median duration of ET use were compared. 
Temporal trends in ET non-initiation, non-adherence, and duration were observed using 
linear and logistic regression models, controlling for age and race. A series of multiple 
regression models were built to explore the association of demographic, clinical, and 
pharmaceutical factors with ET usage duration. Qualitative data analysis was completed 
by a three-member research team using an inductive narrative approach. Themes were 
examined by participant decision to continue or discontinue ET.  
Fifty three percent of women in the sample did not initiate ET, with highest non-
initiation rates among African Americans and survivors under age 50. Of those who did 
initiate ET, 42% were non-adherent with a median ET usage duration of 37 months. 
Twenty one percent of initiators continued taking ET for five years or more. There was 
no change in the odds of ET non-initiation from 2000 – 2004. The odds of ET non-
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initiation decreased from 2005 – 2009 but then increased from 2010 – 2014. There was 
no change in the odds of ET non-adherence from 2000 – 2006, but from 2007 – 2012, the 
odds of ET non-adherence decreased each year. The average ET usage duration was 
increasing from 2000 – 2006 but decreasing from 2006 – 2012. 
Multiple linear regression analysis showed that none of the demographic or 
clinical factors tested were significantly associated with ET usage duration. The type of 
ET taken as well as receipt of the prescriptions that could have been used to alleviate side 
effects were significantly associated. Participants’ feedback centered on a risk vs. benefit 
analysis unique to the individual survivor. Main themes included the importance of an 
open, honest patient/provider relationship and the need for personal information seeking 
and affirmation in the decision to take ET. There was clear support for the utility of 
multidisciplinary cancer care teams and incorporating integrative approaches.  
This study provides a realistic picture of the challenges associated with ET usage 
among South Carolina Medicaid breast cancer patients. It particularly highlights more 
opportunity for improvement in ET initiation, adherence, and duration among younger 
women of lower socioeconomic status. Our study also highlights the potential value of 
concurrent prescriptions for improving ET usage duration, with an optimal intervention 
point before 14 months post ET initiation. Further research is needed to test 
pharmacologic interventions that may significantly increase ET duration as well as other 
non-pharmacologic strategies for side effect management. Research employing patient-
centered perspectives is imperative. Novel and practical patient-centered interventions in 
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research exploring openness in the patient/provider relationship, survivor information 
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It is well known that breast cancer is the most common type of cancer in the 
United States, accounting for almost 15% of all new cancer cases and 6.8% of all cancer 
deaths in 2016 (“Cancer Among Women,” 2016; “Cancer of the Breast,” 2016). 
Following surgery, radiation therapy, and/or chemotherapy, a woman with Stage 0-III 
hormone receptor-positive breast cancer is typically prescribed endocrine therapy (ET) 
for five years or longer as part of initial treatment (“Hormonal Therapy,” 2016; “Ten 
Years,” 2014). The purpose of ET is to reduce a woman’s risk of breast cancer 
recurrence. Taking ET (Tamoxifen or an aromatase inhibitor) as prescribed for five years 
can reduce the risk of recurrence by 40% and death by one-third (Early Breast Cancer 
Trialists' Collaborative Group [EBCTCG], 2005).  
Research and clinical practice confirm that rates of ET initiation (i.e. filling the 
first prescription), adherence (i.e. following the provider’s recommendations day-to-day 
regarding the timing, dosage, and frequency of the ET), and continuation (i.e. the act of 
continuing ET for the prescribed duration) are quite low (Cramer et al., 2008; Hershman 
et al., 2011; Partridge, Wang, Winer, & Avorn, 2003; Wheeler et al., 2014). Studies 
conducted in the North Carolina and New York Medicaid populations showed non-
initiation rates around 50% without intervention (Wagner et al., 2016; Wheeler et al., 
2014). A systematic review by Murphy et al. (2012) showed that adherence ranged from 
 2 
41–72% and discontinuation ranged from 31–73%, measured at the end of 5 years of 
treatment.  
Knowledge of the population affected by ET non-initiation, non-adherence, and 
early discontinuation in South Carolina is limited, as is knowledge of how to improve the 
ET experience for patients, both in South Carolina and across the nation.  The few studies 
that have addressed interventions showed little to no improvement over usual care 
(Hurtado-de-Mendoza, Cabling, Lobo, Dash, & Sheppard, 2016; Ekinci et al., 2018). The 
overall aim of this research is to inform the development of future interventions by 1) 
describing ET non-initiation, non-adherence, and duration by age, race, and temporal 
trend and 2) identifying demographic, clinical, and pharmaceutical factors that are 
associated with an individual’s ET usage duration for South Carolina Medicaid-enrolled 
women who had hormone receptor-positive breast cancer diagnosed between 2000 and 
2014. This third aim of this research is to inform future interventions by understanding, 
from the survivor perspective, which modifiable factors could have the greatest impact on 
the likelihood of ET continuation. 
 
Problem Statement 
ET discontinuation and non-adherence rates remain high despite the use of ET for 
decades as the primary means of reducing the risk of breast cancer recurrence in women 
with hormone receptor-positive Stage 0-III disease (EBCTCG, 2005; Reynolds & 
Higgins, 2013). The only known published research regarding ET usage among South 
Carolina women was conducted among Medicaid enrollees by Wu and Lu (2013) and 
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Felder et al. (2016). Wu and Lu examined the association between adherence to hormone 
therapy and healthcare costs from 2000-2008 and found no significant difference in total 
healthcare costs between the adherent and non-adherent women. Felder et al. (2016) 
studied racial differences in the receipt of ET among patients in one health care system 
and found no significant differences by race but overall low usage rates.  
The purpose of the proposed study is to further expand on the work of Wu and Lu 
(2013) and Felder et al. (2016) to examine the ET non-initiation, non-adherence, and 
duration of SC women recipients diagnosed with hormone receptor-positive breast cancer 
after 2000 and to ultimately inform a patient-centered intervention to improve ET usage. 
Specifically, the aims of this study are 1) to describe ET non-initiation, non-
adherence, and duration by age, race, and temporal trend and 2) to identify 
demographic, clinical, and pharmaceutical factors that are associated with an 
individual’s ET usage duration for South Carolina Medicaid-enrolled women who 
had hormone receptor-positive breast cancer diagnosed between 2000 and 2014; and 
3) to understand from the survivor perspective which modifiable factors could have 
the greatest impact on the likelihood of ET continuation. It is imperative that research 
be conducted that employs a patient-centered perspective. The knowledge gained through 
further study can be integrated in developing future patient-centered interventions to 






The Health Belief Model was used as the theoretical framework to explain what is 
currently known about ET usage and informed the study design. The Health Belief Model 
was developed in the 1950s by Hochbaum, Rosenstock, and Kegels of the U.S. Public 
Health Services (“Health Belief Model,” n.d.). Since then, it has been widely used to 
study various preventive health and clinic use behaviors among many populations 
(Baghianimoghadam et al., 2013; Farma, Jalili, Zareban, Pour, 2014; Holwerda, 2000; 
VanDyke & Shell, 2016; Wang et al., 2014).  
The study used the original Health Belief Model, which consists of six major 
constructs: perceived susceptibility, perceived seriousness, perceived benefits, perceived 
barriers, modifying variables, and cues to action. In the study context, these constructs 
were briefly defined as follows (Hayden, 2013; “Health Belief Model,” n.d.): 
 Perceived susceptibility: A woman’s assessment of the chances of breast 
cancer recurrence 
 Perceived seriousness: A woman’s assessment of the severity of breast cancer 
recurrence 
 Perceived benefits: A woman’s degree of belief in the efficacy of ET in 
reducing breast cancer recurrence 
 Perceived barriers: A woman’s assessment of the costs of ET continuation and 
adherence 
 Modifying variables: Personal factors that affect ET usage 
 Cues to action: Factors that help “activate readiness” in a woman taking ET 
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See Appendix A for a detailed diagram of the Health Belief Model applied to this 
study on ET usage among South Carolina breast cancer survivors. 
The study also employed grounded theory in interpreting its qualitative findings. 
This theory was first published by Glaser & Strauss in 1967 (Cohen & Crabtree, 2006). 
Grounded theory is an empirical, inductive, systematic process in which theoretical 
insights are generated from the data collected and are not established prior to the study; 
however, it is possible that the findings may reveal that an established theory is the most 
fitting for their interpretation (Chapman, Hadfield, & Chapman, 2014; Cohen & Crabtree, 
2006; Hussein, Hirst, Salyers, & Osuji, 2014). For example, it was hypothesized that 
based on cancer survivorship and medication adherence literature, Michel’s Uncertainty 
in Illness Theory, Theory of Planned Behavior, a quality of life theory, or a stress and 
coping theory may be suited to the findings. Nevertheless, in keeping with the principles 
of grounded theory, this was not assumed nor determined until data analysis (Hussein, 
Hirst, Salyers, & Osuji, 2014). As pointed out by Achora and Matua (2016), although 
grounded theory was employed, the research questions, data collection methods, and 






To provide background and context for the study, several pertinent topics were 
surveyed in the literature including breast cancer epidemiology; the role and history of 
ET in breast cancer treatment; the problem of ET non-initiation, non-adherence, and 
discontinuation; and existing interventions. 
 
Breast Cancer Epidemiology 
The human body is composed of trillions of cells that grow and divide to form 
new cells that take the place of old or damaged cells as they die (“What is Cancer?,” 
2015). “Cancer” is a broad term describing a condition in which genetic changes cause 
cells to grow and divide endlessly, even though not needed by the body (“What is 
Cancer?,” 2015). These additional cells can form tumors that are usually named for the 
part of the body where they originate (“Breast Cancer Facts,” 2015). For example, breast 
cancers begin in parts of the breast, usually the ducts or lobules (“Breast Cancer Facts,” 
2015). 
Female breast cancer is currently the most common type of cancer in the United 
States, followed by lung and bronchus cancer, prostate cancer, colon and rectum cancer, 
and bladder cancer. In 2016, there were approximately 246,660 new cases of female 
breast cancer, which accounted for 14.6% of all new cancer cases, and there were 40,450 
estimated deaths from female breast cancer, which accounted for 6.8% of all cancer 
deaths (“Cancer of the breast,” 2016). From 2006-2012, 89.7% of persons with female 
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breast cancer survived five years or more post-diagnosis (“Cancer of the breast,” 2016). 
From 2009-2013, female breast cancer was most commonly diagnosed among women 
ages 55-64 (25.7%), and women ages 45-74 accounted for almost 70% of all new breast 
cancer cases (“Cancer of the breast,” 2016). The female breast cancer incidence rate from 
2009-2013 was highest among white women (128.0 per 100,000), followed closely by 
black women (125.2 per 100,000); however, the number of deaths was higher for black 
women (29.6 per 100,000) compared to white women (21.0 per 100,000) (“Cancer of the 
Breast,” 2016).  
South Carolina ranks 20th for female breast cancer incidence when compared to 
the rest of the United States (Bolick & Clugstone, 2016). From 2009-2013, South 
Carolina experienced the most new cases of lung cancer, followed by female breast 
cancer (Bolick & Clugstone, 2016). On average, 3,606 new cases of female breast cancer 
occurred annually in the state from 2009-2013 with an incidence rate 125.9 per 100,000 
(Bolick & Clugstone, 2016). The American Cancer Society expected that South Carolina 
would experience 4,250 new cases of breast cancer in 2017 (“Cancer Facts,” 2017).  
South Carolina has a higher female breast cancer mortality rate (2009-2013) 
compared to the U.S., ranking 14th when compared to the rest of the nation’s states (22.4 
per 100,000 versus 21.5 per 100,000) (“Breast Cancer in South Carolina,” 2016). Similar 
to national trends, the breast cancer mortality rate is higher for South Carolina black 
women compared to white women (28.7 per 100,000 versus 20.3 per 100,000) (“Breast 
Cancer in South Carolina,” 2016). 
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With advances in breast cancer screening and treatment, the population of female 
breast cancer survivors in the United States continues to grow and was estimated at 
3,560,570 as of January 2016 (“Cancer Treatment & Survivorship,” 2016). This 
population is expected to total 4,571,210 by 2026 (“Cancer Treatment & Survivorship,” 
2016). Female breast cancer survivors can experience long-term effects from their 
surgical, radiation, or chemotherapy treatments, including numbness, tingling, or 
tightness in the chest wall, arms, or shoulders; persistent nerve pain in the chest wall, 
armpit, and/or arm after surgery; or other types of chronic pain (“Cancer Treatment & 
Survivorship,” 2016). In addition, breast cancer treatments can affect a woman’s fertility 
and menopausal status and put a woman at an increased risk for osteoporosis (“Cancer 
Treatment & Survivorship,” 2016). 
An important issue for breast cancer survivors is the risk of cancer recurrence. 
Once the initial cancer is treated, there remains the risk of the cancer recurring either 
locally in the breast or metastasizing (i.e. spreading to other parts of the body). The 
amount of risk for secondary cancers depends on many different factors related to the 
original cancer and the initial treatment. Some of these factors can include the hormone 
receptor status, human epidermal growth factor receptor 2 (HER2), whether the tumor 
margins and lymph nodes contain cancer cells, whether a woman had a lumpectomy (i.e. 
breast conserving surgery) and radiation therapy versus a mastectomy, and whether a 
woman had chemotherapy (“What are the risks,” 2016). For instance, for women who 
have a lumpectomy and complete radiation therapy, the risk of local recurrence within ten 
years is between three to fifteen percent (Arvold et al., 2011). For women who have a 
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mastectomy and whose lymph nodes do not contain cancer, the chance of local 
recurrence in five years is approximately six percent (Celik, Aydoğan, Yilmaz, Yaşar, & 
Müslümanoğlu, 2016).  
 
Role and History of Endocrine Therapy in Breast Cancer Treatment 
During a biopsy or surgery, cancer cells are tested to determine if they have 
estrogen or progesterone receptors (“Breast Cancer Hormone Receptor,” 2016). Sixty to 
seventy-five percent of cancers are hormone receptor-positive, meaning that the cells test 
positive for estrogen (“Breast Cancer Hormone Receptor,” 2016; Burstein et al., 2014). 
Knowing this status is important in determining the treatment options because after the 
initial chemotherapy, radiation, and/or surgery, if the cancer is hormone receptor-
positive, a woman can be prescribed ET to reduce her risk of breast cancer recurrence. 
Two types of ET that can be used to reduce the risk of breast cancer recurrence 
for women with hormone receptor-positive cancer are Tamoxifen and aromatase 
inhibitors. Tamoxifen is a selective estrogen receptor modulator and blocks estrogen 
receptors in breast cancer cells (“Hormone Therapy,” 2016) and is typically prescribed 
for pre-menopausal women. Aromatase inhibitors (Letrozole/Femara, 
Anastrozole/Arimidex, and Exemestane/Aromasin) are given to women whose ovaries no 
longer produce estrogen (i.e. usually post-menopausal women or women receiving 
ovarian ablation). Aromatase inhibitors block aromatase, an enzyme in fat tissue, from 
making estrogen (“Hormone Therapy,” 2016).  
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The beginnings of understanding the role that estrogen plays in breast cancer can 
historically be traced back to the late 1800s (“Evolution of Cancer,” 2014; Jones & 
Buzdar, 2004). Tamoxifen was originally introduced in 1967 as an antifertility agent in 
rats and was proposed for long term adjuvant therapy ten years later (Jordan, 2006; 
Maximov, Lee, & Jordan, 2013). In 1977, research targeting the aromatase enzyme also 
began (Maximov, Lee, & Jordan, 2013). Selective aromatase inhibitors were first 
reported in 1973 and began testing in clinical trials in the 1990’s (Jordan & Brodie, 
2007).  
 For decades, Tamoxifen was prescribed for five years as standard treatment. In 
2014, the American Society of Clinical Oncology (ASCO) convened a committee to 
conduct a systematic review to examine evidence from 2009 through 2013 trials 
regarding extending the duration of Tamoxifen from five to ten years (Burstein et al., 
2014). The results of the MA.17R trial were also released in 2016 and showed benefits of 
taking aromatase inhibitors for up to ten years over five years (Goss et al., 2016). As of 
2016, ASCO and the National Comprehensive Cancer Network generally recommend the 
following regimens for women with Stage I-III breast cancer (“Hormonal Therapy for 
Early-Stage,” 2016; NCCN Guidelines, 2014; NCCN Guidelines, 2016):  
 Premenopausal women should take Tamoxifen for five years possibly combined 
with ovarian suppression or ablation. At the end of five years, if the woman is still 
premenopausal, she should consider taking Tamoxifen for another five years or 
stop taking ET. At the end of the first five years, if the woman is postmenopausal, 
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the woman could take aromatase inhibitors for five years or consider taking 
Tamoxifen for another five years. 
 An alternate to Tamoxifen as initial treatment for premenopausal women is to 
take an aromatase inhibitor for five years with ovarian suppression or ablation. 
 Postmenopausal women have the option to take an aromatase inhibitor for five 
years, consider Tamoxifen for ten years if aromatase inhibitors are not an option, 
or take Tamoxifen for a period of time, followed by an aromatase inhibitor until 
five or ten years of ET duration is reached. 
 
Problem of Endocrine Therapy Non-initiation, Non-adherence, and Discontinuation 
Numerous studies have been conducted to examine the problem of ET non-
initiation, non-adherence, and discontinuation. These studies estimate the percentage of 
patients who do not initiate, are non-adherent, or discontinue as well as identify risk 
factors for non-initiation, non-adherence, or discontinuation. Studies conducted in 
Medicaid populations in New York and North Carolina showed non-initiation rates 
around 50% without intervention (Wagner et al., 2016; Wheeler et al., 2014). The results 
of four major systematic reviews will be presented. 
Gotay and Dunn (2011) conducted a systematic review of studies published 
between 2007 and 2011 examining ET use in clinical practice with a sample size of at 
least 100. Fourteen studies met the inclusion criteria. The review showed that adherence 
rates after one year of ET usage ranged from 77–88%, and adherence rates in years four 
and five ranged from 27–49%. Middle-aged women (e.g. 50–69 years) appeared to be 
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most adherent. Low social support was negatively associated with adherence. Being 
married produced mixed results. Greater comorbidity and drug cost were also negatively 
associated with adherence. Side effects such as hot flashes, mood disturbances, and 
muscle aches largely contributed to patients not taking ET as did lack of communication 
from their providers regarding the importance of taking ET. Studies that examined use of 
both Tamoxifen and aromatase inhibitors reported better adherence to aromatase 
inhibitors, although the groups were different based on important factors such as age.  
Murphy et al. (2012) conducted a systematic review to examine literature from 
1998-2012 related to ET adherence and continuation in routine clinical settings, 
excluding clinical trials. Twenty-nine studies met the review inclusion criteria. The 
review showed that the prevalence of adherence ranged from 41–88% among Tamoxifen 
users and 50–91% for aromatase inhibitor users (Murphy et al., 2012). The percentage of 
Tamoxifen users who discontinued treatment ranged from 15–20% in the first year of 
therapy to 31–60% at the end of five years. The percentage of aromatase inhibitor users 
who discontinued treatment ranged from 5–25% during the first two years of therapy. 
Studies that examined users of both Tamoxifen and aromatase inhibitors aggregately 
showed discontinuation rates that ranged from 32–73% at the end of five years. 
Prospective studies describing Tamoxifen discontinuation revealed rates of 21%, 15%, 
and 31% at the end of 27, 33, and 63 month study periods, respectively. The systematic 
review also showed that women who originally took Tamoxifen and switched to an 
aromatase inhibitor after two to three years were less likely to adhere to treatment. The 
following factors were found to be negatively associated with adherence: Extremes of age 
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(i.e., older or younger), increasing out-of-pocket costs, follow-up care with a general 
practitioner (vs. cancer specialist), and treatment side effects. The following factors were 
found to be positively associated with adherence: taking more medications at baseline, 
referral to an oncologist, and earlier year at diagnosis. Low social support was found to 
be negatively associated with continuation. 
 Chlebowski, Kim, and Haque (2014) conducted a comprehensive literature review 
that showed the following factors were associated with ET discontinuation: side effects, 
higher comorbidity, financial considerations or low socioeconomic status, very young or 
older age, lack of provider recommendation, perception of low risk of recurrence, lack of 
social support, follow-up care with general practitioner vs. oncologist, African American 
race/ethnicity, cigarette smoking, and alcohol use. The presence of anxiety/depression 
was linked to better adherence. Findings regarding adherence stratified by race/ethnicity 
were mixed. 
 Roberts, Wheeler, and Reeder-Hayes (2015) conducted a systematic review of 
literature to determine racial/ethnic and socioeconomic disparities in ET adherence. The 
literature search included studies from 1978-2014. Fourteen articles met the inclusion 
criteria. Half of the articles showed there was significant racial/ethnic variation in ET 
usage, with four of the studies showing that Black women were less likely to initiate or 
adhere to ET than women of other racial/ethnic groups. Half of the articles showed there 
was no effect of race/ethnicity on ET use. Across racial/ethnic groups, side effects were 
among the top reported barriers to ET use. The relationship between cost and ET use is 
unclear, as results varied widely among studies. Referral to a medical oncologist was 
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positively associated with ET use. Among low-income women, higher perceived efficacy 
of patient-physician interactions and the quality of patient-provider communication was 
associated with increased ET continuation. Social support was not strongly associated 
with ET use. 
 Though the systematic reviews included qualitative studies, a two pertinent 
qualitative studies will be highlighted individually that are especially relevant to the 
proposed study. J Van Londen et al. (2015) conducted focus groups with fourteen breast 
cancer survivors taking adjuvant ET at the University of Pittsburgh. Results showed that 
initially, the women did not view taking ET as a decision but felt it something necessary 
for their future health. Once unanticipated symptoms occurred (including vasomotor 
symptoms, sexual dysfunction, insomnia, fatigue, cognitive dysfunction, pain, functional 
limitations, mood disturbance, and anxiety), women were uncertain about the cause of 
their symptoms, felt their friends and families could not relate, and felt that talking with 
their providers about the symptoms was difficult and could be seen as a sign of 
emotional/psychological problems. Frustration ensued, and women expressed 
dissatisfaction with the symptom management information from healthcare providers and 
found few effective and tolerable symptom management strategies. These issues caused 
the women to rethink their decision to take ET and to reweigh the pros and cons of 
whether the reduced risk of recurrence was worth losing their current quality of life. 
 Pellegrini et al. (2010) conducted semi-structured interviews with 34 women aged 
35-65 at two French cancer centers. All participants were breast cancer patients and had 
been prescribed Tamoxifen. Findings showed that women confused the hormonal/anti-
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hormonal effects of Tamoxifen and how it was related to contraceptive pills and hormone 
replacement therapy. Many women admitted lacking knowledge about Tamoxifen’s 
action and expressed doubts as to its necessity. A common theme women expressed was 
a dislike of drugs and a fear that Tamoxifen could cause other types of cancer. Women 
also expressed concern for the lack of treatment options for side effects, especially hot 
flashes and tiredness, and the need for clarification about the causes of perceived 
menopausal symptoms. Women said they received conflicting messages from their 
oncologist, other patients, and the internet. Women shared the distress and tension they 
felt while taking Tamoxifen because of the paradoxical situation that the drug’s purpose 
was to save life but it was causing their youthful looks and femininity to diminish. 
 Research is needed on modifiable factors associated with ET use as well as the 
development of behavioral and educational interventions intended to improve initiation, 




Hurtado-de-Mendoza et al. (2016) published what the authors describe as the first 
systematic literature review examining behavioral interventions aimed at improving 
hormone therapy adherence. Five articles met the study inclusion criteria. The Patient’s 
Anastrozole Compliance to Therapy (PACT) was used in three of the studies. PACT 
employed educational materials (i.e. nine pamphlets and ten personal letters) about breast 
cancer, treatments, medication side effects, strategies for enhancing adherence, and 
information about diet and physical exercise as well as monthly reminders about 
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medication adherence.  Variations of PACT were tested in three of the five studies, which 
were conducted in Germany, eighteen countries, and China, respectively. Another study 
consisted of a three-arm randomized controlled trial. Participants in one arm received 
personalized motivational reminder letters containing information including the 
importance and impact of disease, effects of AIs, and nurse contacts to answer questions 
as well as a breast cancer leaflet. Those assigned to the second arm received telephone 
calls from a nurse who conducted motivational interviewing and provided motivation, 
reminders, and individualized information regarding the patient’s specific problems. 
Finally, a third intervention used a two-arm randomized trial design to assign patients to 
an enhanced standard of care arm with written resource patient navigation information or 
to a written information plus one structured phone interview by a patient navigator. None 
of the interventions tested in the five studies significantly improved adherence or 
continuation when compared to usual care.  
 Studies have also tested novel communication strategies for patients and 
providers. Epstein et al. (2015) developed and tested a bi-directional text messaging 
application that simultaneously assesses patient adherence to ET and provides real-time 
feedback to the provider. The pilot study of 62 patients showed found the application 
helpful, easy to use, and not time consuming, with none of the patients discontinuing ET 
compared to nine percent of historical controls. 
 Another e-Health intervention is currently taking place in Montreal, Canada with 
results expected by June of 2018 (Meguerditchian et al., 2016). This e-Health tool 
integrates real-time analysis of health administrative claims data to provide point-of-care 
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decision support for clinicians. The purpose of the study is to determine the effectiveness 
of the intervention in reducing rates of ET discontinuation, to understand patient-level 
factors related to ET discontinuation, and to assess the integration of e-Health alerts 
regarding deviations from best practices in ET administration by cancer care teams. 
  Some interventions focus on relieving side effect symptoms and increasing 
quality of life through various means including exercise, sleep aids, and mindfulness. 
These studies typically have not measured whether the improvement in side effect 
symptoms or quality of life actually has improved ET usage. Hojan, Molinska-Glura, and 
Milecki (2012) studied the results of an aerobic exercise program for a sample of forty-
one premenopausal women. The program began six months after ET initiation. The 
program took place at the Rehabilitation Ward in the Greater Poland Cancer Centre. 
Body composition, body physique, and Quality of Life were evaluated before and after 
six, 12, and 18 months of ET using dual-energy x-ray absorptiometry (DXA) scans, 
anthropometric measurement techniques, and questionnaires from the European 
Organization for Research and Treatment of Cancer, respectively. In the eighteenth 
month of the study, results showed a significant increase in overall quality of life and 
functioning levels, improved positive body image, and a reduction in symptom levels.  
The Yale Fitness Intervention Trial sought to determine the effects of a twelve-
month aerobic-resistance exercise intervention compared to a home-based physical 
activity group (Knobf et al., 2016). Seventy-six patients were randomized to the exercise 
intervention, and 78 were randomized to the home group. When compared at one year, 
participants on Tamoxifen or no ET did not lose a significant amount of bone mineral 
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density except in the femoral neck, but participants on aromatase inhibitors had 
significant bone mineral density loss at all sites. Thus, the intervention proved ineffective 
for patients taking aromatase inhibitors. 
Marshall-McKenna et al. (2015) studied the effect of a cool pad pillow topper 
versus standard care for women taking ET suffering from hot flushes and insomnia. 
Thirty-seven women were randomized to the intervention arm, and thirty-eight were 
randomized to the control arm. Sleep efficiency score increased twice as much in the 
intervention arm between two to four weeks of the intervention. There was also 
significantly greater reductions in hot flushes and the depression score for the 
intervention arm.  
 Mebis et al. (2016) reported on an eight-week Mindfulness-Based Stress 
Reduction (MBSR) intervention provided to twenty newly diagnosed breast cancer 
patients taking Tamoxifen. MBSR is a structured group intervention that is based on 
meditation and its daily life application. MBSR has proven effective when used to help 
cancer patients but had not yet been tested specifically with ET patients. Mebis et al. 
(2016) found that after receiving the MBSR intervention, the depression anxiety stress 
scale scores of the twenty patient cohort significantly decreased; however, the quality of 
life scale scores also decreased during the intervention but were improved over baseline 
six months post-intervention. 
Future research should test these interventions’ impact on ET usage. Other 
approaches for improving ET adherence and continuation have been suggested such as 
enhancing nurse-patient communication regarding ET; clinical approaches to early 
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recognition and treatment of genitourinary side effects of ET; and utilizing patient 
support groups, and online communities and blogs; but these have yet to be tested. (Gotay 
& Dunn, 2011; Miaskowski, Shockney, & Chlebowski, 2008; Sousa et al., 2017).  
 Although the results of systematics reviews show little to no improvement in ET 
usage, there are certainly elements of interventions that have proven successful in 
decreasing side effects or increasing quality of life that have potential to improve ET 
usage. More research is needed to better understand how and when to intervene to 
improve ET usage among South Carolina women. More information is required to inform 
future practice and intervention, including which populations are most in need, how ET 
usage has changed over time, factors that are associated with longer ET usage, and which 







This dissertation research focused on female, South Carolina residents diagnosed 
with stage 0-III or unstaged hormone receptor-positive breast cancer and who were age 
18-64 at diagnosis. This research was guided by six primary research questions: 
AIM 1: To describe ET non-initiation, non-adherence, and duration by age, 
race, and temporal trend 
Question 1: How do rates of ET non-initiation, non-adherence, and duration vary 
by age and race?  
Hypothesis 1: ET non-initiation, non-adherence, and duration rates are worse 
among younger women and women of African American race. 
Question 2: How have rates of ET non-initiation, non-adherence, and duration 
changed during the study period? 
Hypothesis 2: There has been no change over the study period in ET non-
initiation, non-adherence, and duration. 
AIM 2: To identify demographic, clinical, and pharmaceutical factors that 
are associated with an individual’s ET usage duration 
Question 3: Which demographic, clinical, and pharmaceutical factors are 
associated with an individual’s ET usage duration? 
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 Demographic: race (white, African American, or other), age at diagnosis, marital 
status (married/unmarried), and rural/urban residency status (2013 Rural-Urban 
Continuum Codes) 
 Clinical: SEER summary breast cancer stage, receipt of chemotherapy (yes/no), 
and receipt of radiation therapy (yes/no) 
 Pharmaceutical: Type of endocrine therapy (Tamoxifen, Anastrozole/Arimidex, 
Exemestane/Aromasin, Letrozole/Femara, switched between aromatase inhibitors, 
switched between Tamoxifen and aromatase inhibitors), and filled alpha-agonist 
hypertensives prescription (yes/no), filled antidepressants prescription (yes/no), 
filled anticonvulsants prescription (yes/no), filled adrenals prescription (yes/no), 
filled nonsteroidal anti-inflammatory agents prescription (yes/no), filled anti-
inflammatory agents prescription (yes/no), and filled vitamins prescription (B, C, 
D, K, and/or multivitamin) (yes/no). 
Hypothesis 3: Women taking Tamoxifen will have lower ET usage duration than 
women taking aromatase inhibitors. Filling prescriptions for drugs known to alleviate 
side effects will be associated with increased ET usage duration. 
AIM 3: To understand from the survivor perspective which modifiable 
factors could have the greatest impact on the likelihood of ET continuation. 
Question 4: What are women’s’ perceptions regarding susceptibility/severity of 
breast cancer recurrence? 
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Hypothesis 4: Women’s susceptibility to breast cancer recurrence will be 
influenced by provider-patient communication. Women will perceive recurrence as 
severe but also be influenced by short-term quality of life preferences. 
Question 5: What are the perceived benefits/barriers to ET continuation? 
Hypothesis 5: Side effects will emerge as a major perceived barrier to ET 
continuation. 
Question 6: What are the cues to action that encourage and support ET 
continuation? 
Hypothesis 6: Provider-patient communication will play a key role in supporting 
ET continuation. 
 
Overall Research Design 
This study utilized a convergent parallel mixed methods design. A mixed methods 
design was chosen because the quantitative and qualitative approaches were structured to 
answer different but complementary questions. By choosing the convergent parallel 
design, the quantitative and qualitative data collection and analyses were able to take 
place simultaneously (Creswell & Clark, 2007). Their results were combined to provide a 
richer multidimensional understanding of the problem of ET non-initiation, non-
adherence, and discontinuation than one approach alone (Curry & Nunez-Smith, 2014). 




Figure 3.1 Convergent parallel mixed methods study design 
 
The methodology for the quantitative and qualitative branches of the study are 
described separately in the following sections. Both branches of the study include female 
South Carolina residents ages 18-64 at diagnosis with stage 0-III or unstaged hormone 
receptor-positive breast cancer; however, the individual women sampled in the 
qualitative study may or may not have been included in the quantitative study. See 
Appendix B for a table of variables that were used in the study. 
The results of the quantitative and qualitative studies were used in conjunction to 
better inform emerging interventions. By highlighting how ET usage rates have changed 
since 2000 and which subgroups are in need of particular attention, interventions can 
glean from past improvements and use resources more effectively. Demographic, clinical, 
and pharmaceutical factors that are associated with longer ET usage duration can be 
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highlighted and tested in interventions. The results generated from the quantitative 
studies can be better validated and further explained by the qualitative study. 
Understanding from the survivor perspective which modifiable factors could have the 
greatest impact on the likelihood of ET continuation will be key to successful future 
interventions. 
 
Quantitative Research Design 
The aim of the quantitative study is 1) to describe ET non-initiation, non-
adherence, and duration by age, race, and temporal trend and 2) identify demographic, 
clinical, and pharmaceutical factors that are associated with an individual’s ET usage 
duration.  
Data 
South Carolina Central Cancer Registry (SCCCR) incidence data from 2000-2014 
was used to identify the study sample and then linked with South Carolina Medicaid 
prescription claims and administrative data from 2000 through September 2016. 
Variables were obtained from the SCCCR data and Medicaid prescription claims and 
administrative data as indicated in Appendix B. Non-initiation, non-adherence, and 
duration outcomes were studied through the Medicaid prescription claims data.  
The data were linked by South Carolina Department of Revenue and Fiscal 
Affairs using probabilistic match by patient first name, last name, social security number, 
and date of birth. Data was de-identified prior to release to the researchers. Clemson 
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University (IRB2017-133) and South Carolina Department of Health and Environmental 
Control Institutional Review Boards approved the study. 
Sample 
This retrospective cohort study included SC women ages 18-64 at diagnosis with 
Stage 0-III or unstaged hormone receptor-positive breast cancer diagnosed between 2000 
and 2014 (N=34,791). Breast cancer survivors who had SEER summary stage 7 cancer 
(N=1,531), who did not have estrogen receptor-positive cancer (N=5,183), who had prior 
cancer diagnoses (N=3,016), or whose cancer was identified through autopsy or death 
certificate (N=72) were excluded. After linking with SC Medicaid prescription data, 
breast cancer survivors who did not meet Medicaid eligibility inclusion criteria (i.e. no 
prescription data; N=18,762 or dually enrolled in Medicare; N=2,397) were also 
excluded. Those who were dually enrolled in Medicare were excluded because Medicare 
prescription claims were not available and therefore, ET usage could not be reliably 
tracked. After exclusions, there were 3,830 breast cancer survivors included in this study.  
Dependent Variables 
ET was defined as Tamoxifen or one of the following aromatase inhibitors: 
Anastrozole/Arimidex, Letrozole/Femara, or Exemestane/Aromasin, which were 
identified using National Drug Codes from the Medicaid prescription claims. Non-
initiation was defined as not having any Medicaid prescription claims in the entire study 
period (from 2000-2016). The non-initiation rate was calculated by dividing the number 
of women who were ET non-initiators by the total number of eligible women (N=3,830). 
Non-adherence was defined as an ET medication possession ratio of less than 80 percent, 
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meaning that the pill supply covered less than 80 percent of the days from the first ET 
prescription dispense date through the last (Hershman et al., 2010). Duration of ET usage 
was calculated as the number of months between the first and last ET prescription 
dispense date. The proportion of women taking ET for at least 5 years was calculated by 
dividing the total number of women taking ET for at least 5 years by the total number of 
women initiating ET.  Non-adherence and duration were calculated using the date 
dispensed and days supplied variables from the South Carolina Medicaid pharmacy 
claims file. 
Independent Variables 
For Research Questions 1-2 (Aim 1), the independent variables were year of 
breast cancer diagnosis, age at diagnosis (centered at mean), and race (0 = White, 1 = 
African American).  
For Research Question 3 (Aim 2), independent variables included the factors 
hypothesized to be associated with ET usage duration based on literature review. The 
following demographic, clinical, and pharmaceutical factors were examined: 
• Demographic: race (White, African American, or other), age at diagnosis, 
marital status (married/unmarried), and rural/urban residency status (2013 Rural-
Urban Continuum Codes) 
• Clinical: SEER summary breast cancer stage, receipt of chemotherapy (yes/no), 
and receipt of radiation therapy (yes/no) 
• Pharmaceutical: Type of endocrine therapy (Tamoxifen, Anastrozole/Arimidex, 
Exemestane/Aromasin, Letrozole/Femara, switched between aromatase inhibitors, 
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switched between Tamoxifen and aromatase inhibitors), and filled alpha-agonist 
hypertensives prescription (yes/no), filled antidepressants prescription (yes/no), 
filled anticonvulsants prescription (yes/no), filled adrenals prescription (yes/no), 
filled nonsteroidal anti-inflammatory agents prescription (yes/no), filled anti-
inflammatory agents prescription (yes/no), and filled vitamins prescription (B, C, 
D, K, and/or multivitamin) (yes/no). The prescriptions were identified by 
therapeutic class code and measured as ever having filled prescription during the 
study period as evidenced by Medicaid claims. 
Provider specialty data had a high number of missing values and therefore was not 
included in the study. 
Statistical Analysis: Aim 1 
Demographic characteristics were compared between ET initiators and non-
initiators using Chi-square tests. Relative risk was calculated for ET non-initiation for 
each of the age/race subgroups, with white/age ≥ 50 years as the reference group.  
ET non-adherence and usage duration analyses were conducted among women 
who had filed at least one ET prescription claim through South Carolina Medicaid and 
who were diagnosed between 2000 – 2012 (N=1,366). Women diagnosed in 2013 and 
2014 were excluded due to the shortened follow-up time since prescription records were 
only available through 2016. Chi-square tests were used to test for a difference in non-
adherence rates among age/race subgroups (i.e. White/age < 50 years, African 
American/age < 50 years, White/age ≥ 50 years, African American/age ≥ 50 years). 
Relative risk of ET non-adherence was calculated for each of the age/race subgroups, 
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with White/age ≥ 50 years as the reference group. Kruskal Wallis tests were used to test 
for a difference in median duration of ET usage by age/race subgroups as previously 
defined.  
We also examined temporal trends in endocrine therapy (ET) non-initiation, non-
adherence, and duration. Temporal trend was measured by calendar year of breast cancer 
diagnosis. The objective was to study participants in groups by year of breast cancer 
diagnosis since much of the information and motivation a woman receives for taking ET 
in the long-term is provided in the initial conversation with a provider when the patient 
receives the first ET prescription.  
We used binary logistic regression to model whether an individual initiated ET or 
not. We also used binary logistic regression to model whether an individual was adherent 
to ET or not. We used ordinary least squares regression to estimate an individual’s ET 
usage duration in months. In each of the three models, we controlled for the covariates 
age (continuous variable centered at the mean) and race (0 = White, 1 = African 
American). 
The data was first examined visually and descriptive statistics were calculated. 
The data did not meet the assumptions for linearity for any of the three outcomes, so non-
linear time trend models were chosen. Non-initiation rates resembled a cubic pattern, so 
the time period was divided into three sub-periods to capture different trends occurring 
during these three sub-periods. Non-adherence and duration seemed to generally increase 
until the year 2006 and decrease thereafter, so time was divided into two sub-periods for 
these analyses. 
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To allow for nonlinear changes in ET non-initiation over time, we used a linear 
spline with knots at 2004 and 2009. For non-initiation, we divided time into the periods 
2000 – 2004, 2005 – 2009, and 2010 – 2014. To allow for changes in ET non-adherence 
and duration observed before and after 2006, we used a linear spline with a knot at 2006. 
For non-adherence and duration, we observed changes in the periods 2000 – 2006 and 
2007 – 2012. Wald tests were used to determine whether the coefficients for the different 
time periods were equivalent. Adjusted trends were examined by generating predicted 
probabilities of ET non-initiation and non-adherence as well as average duration. Stata 
14.2 was used for all analyses. 
Statistical Analysis: Aim 2 
Multiple linear regression models were built to explore the impact of 
demographic, clinical, and pharmaceutical factors on ET usage duration in months (α = 
0.05) for survivors diagnosed in 2000 – 2012 who filled at least one ET prescription 
(N=1,399). First, a series of models was made by singularly entering each of the 
independent variables with the dependent variable ET usage duration. Then, the 
combined effect of the independent variables that were significantly associated with the 
dependent variable was examined. Interactions terms were generated for each pair of 
significant independent variables and entered as a block to test for significant association 
with ET usage duration. The final model was generated by removing variables from the 
model that were no longer significant when controlling for other factors and adding the 
significant interaction terms. The final model included ET type; receipt of the following 
concurrent prescriptions: adrenals, nonsteroidal anti-inflammatory agents, anti-
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inflammatory agents, and/or vitamins; and two-way interaction terms for ET 
type/adrenals and anti-inflammatory agents/vitamins. StataMP 14.0 was used for all 
analyses. 
 
Qualitative Research Design 
The qualitative study will aim to understand from the patient perspective which 
modifiable factors have the greatest impact on the likelihood of ET continuation. 
Recruitment 
Breast cancer survivors were recruited through breast cancer support groups and 
advocacy organizations and a local cancer survivorship institute. These included the 
Greenville Health System Center for Integrative Oncology and Survivorship, the Komen 
Foundation, and the South Carolina Witness Project as well as local breast cancer support 
groups. Inclusion criteria for participation were female, English speaker, diagnosed with 
Stage 0-III hormone receptor-positive breast cancer since 2000, completed breast cancer 
treatment, and prescribed endocrine therapy between the ages of 18-64 years. 
Recruitment for the fourth focus group heavily targeted women who had not initiated or 
who had discontinued use of ET. 
Patients meeting the study inclusion criteria were notified about the study during 
clinic visits at the Center for Integrative Oncology and Survivorship. An e-mail invitation 
was sent to a listserv of patients in the Greenville Health System Survivorship Registry, a 
group of cancer survivors who had already consented to receive periodic notifications of 
research studies for possible enrollment. In addition, the Komen Foundation, South 
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Carolina Witness Project, and local breast cancer support groups used the recruitment 
flyer (see APPENDIX C) to publicize the opportunity to participate in the study among 
their members through meeting announcements, personal contact, e-mail, and social 
media posts. 
The recruitment flyer introduced potential participants to the project and invited 
them to participate. Interested participants were directed to call a project team member at 
an advertised phone number if willing to participate in a focus group. The project team 
member receiving the call used a script for screening (see APPENDIX D) interested 
participants and scheduled eligible participants for a focus group date and location. A 
reminder call was made one week prior to the focus group, and a reminder e-mail was 
sent one day prior to the group meeting. A Walmart gift card in the amount of $50 was 
provided to each participant in return for their time and transportation costs.  
Data Collection 
The focus groups lasted approximately 1.5 hours each and were held in neutral, 
private locations. All focus groups were conducted in English by two trained members of 
the project staff. Participants received an informational letter at the beginning of the focus 
group introducing them to the potential benefits and risks of the study. The moderators 
used a focus group guide developed by the research team members with qualitative, 
cancer-focused research experience after reviewing the existing literature to elicit 
participants’ experiences with ET. The guide was driven by elements of the Health Belief 
Model, specifically probing about perceived susceptibility to and seriousness of breast 
cancer recurrence, perceived benefits and barriers to ET continuation, and cues to action 
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that may support or encourage ET continuation. The various probes stimulated discussion 
about specific events and experiences that shaped participants’ opinions and attitudes 
regarding ET usage. The focus group guide is provided in APPENDIX E. Each focus 
group was audio-recorded and then transcribed by a reputable medical transcription 
service and verified by a member of the project staff. The group demographics were 
obtained via a brief, anonymous survey (see APPENDIX F) that was administered prior 
to the focus group. These demographics (e.g. age group, race, sex, ET type) were 
collected for purposes of external validity.  
Data Analysis 
Data analysis was completed by three members of the research team with input 
from a breast cancer survivors’ panel. The team used a grounded theory approach to 
identify themes and an inductive narrative approach to data analysis (Bradley, Curry & 
Dever, 2007; Kidd & Parshall, 2000; Thomas, 2006; Thorne, 2000). The team members 
began by analyzing one of the focus group transcripts to create a codebook.  The 
codebook was expanded as the other three transcripts were analyzed. The analysis team 
followed a process detailed by Miles and Huberman (Miles & Huberman, 1994), dividing 
the coding duties so that each transcript was coded by at least two independent coders. 
The team met during the coding process to address consensus, update the coding 
structure, and revisit any previously coded text as needed. Codes were applied to 
transcripts using Atlas.ti software Version 7.5.10 (Friese, 2013).  
Themes emerged during a subsequent review and analysis of code based queries 
using the Atlas.ti software. A priori codes drawn from the focus group guide, as informed 
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by the Health Belief Model served as the organizing analysis framework. As new themes 
emerged, the narrative was expanded. Two survivors who were not focus group 
participants assisted with identifying themes and expanding the narrative. There were 
fifteen final codes. Themes were examined by participant decision to continue or 
discontinue ET, and quotations exemplifying each theme are provided in the results. 
Patient Engagement Studio Involvement 
The Meharry-Vanderbilt Community-Engaged Research Core began developing 
the idea of a Community Engagement Studio in 2009, based on the idea of the Clinical 
and Translational Research Studio (Joosten et al., 2015). While the Clinical and 
Translational Research Studio convenes a panel of academic experts to provide project-
specific input to researchers, the Community Engagement Studio convenes a panel of 
patients to consult with investigators on specific projects. These patients are viewed as 
consultants as opposed to research subjects and are recruited and paid accordingly. The 
novelty of the Community Engagement Studio as compared to other forms of patient-
centered or community-based participatory research is that the investigators do not spend 
time recruiting the stakeholders (Joosten et al., 2015). The Community Engagement 
Studio staff members recruit and orient stakeholders, arrange and moderate the 
discussion, take notes during the meeting, and prepare a written summary after the 
meeting for the investigator. Through these means, investigator burden is minimized and 
efficiency is maximized (Joosten et al., 2015).  
A team of staff, faculty, and community partners from the Meharry-Vanderbilt 
Community Engagement Studio developed a tool kit that other sites can use to replicate 
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their Community Engagement Studio model. The Greenville Health System has recently 
adapted the Meharry-Vanderbilt Community Engagement Studio model to form their 
own Patient Engagement Studio. The qualitative branch of the proposed research study 
was informed and guided by the input of a general Patient Engagement Studio and a 
breast cancer specific Patient Engagement Studio, both from the Greenville Health 
System.  
A project team member presented the proposed study to the Greenville Health 
System Patient Engagement Studio in January 2017 at the beginning of the study design 
phase to ask for patient input regarding the qualitative study. This studio meets monthly 
to review research and to provide feedback to researchers regarding their projects. Two 
scientists with experience in quality initiatives, two academic physician clinicians from 
the Greenville Health System, a Patient Experience expert, an Engagement Navigator, 
five patient “experts,” and two breast cancer patients were present for the meeting. The 
two breast cancer patients were recruited specifically for this studio meeting due to the 
nature of the research topic.  
The studio provided recommendations for patient recruitment including potential 
concerns of Medicaid patients and the need to be sensitive to those during recruitment 
planning, differences in older and younger patients and the need for clarifying the study 
population and research questions accordingly as well as distrust or disinterest among 
patients receiving a flyer through the mail and ways to overcome that barrier. Other 
tangible suggestions included conducting the focus groups in a neutral location in the 
community as opposed to a healthcare office, the appropriate amount to provide for 
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incentives, and adding an anonymous demographic survey to the focus groups so that the 
population could be generally described. Patients were intrigued by the project and its 
potential significance. 
In addition to this first interaction with the Greenville Health System Patient 
Engagement Studio, a breast cancer specific Patient Engagement Studio was recruited by 
the Greenville Health System Patient Engagement Studio director. This breast cancer 
specific Patient Engagement Studio reviewed and provided input on the Health Belief 
Model framework and the focus group guide in June 2017. Feedback from the Studio 
included the following points, all of which were incorporated into the recruitment and 
production of the focus groups: 
• Be more neutral in the recruitment flyer language. For instance, “Taking 
endocrine therapy is a ‘challenge’ for many women, rather than a using a negative 
word such as “struggle.” 
• In recruitment, be specific about the names of the medications since some 
patients may not recognize the term “endocrine therapy.” 
• Be more direct during the focus group introduction in telling women that if they 
have shared a lot, we might call on someone else (and ask you to stop) so that 
others can have a chance to share. 
• When asking women to give the name they would like to be called by, don’t say 
“or a pseudonym.” That “creeps people out” and makes them feel scared of why 
this is so top secret. They’ve volunteered to come and want to share, so don’t 
make it weird. 
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• When asking about the initial conversation between the patient and “the” doctor, 
be aware that the patient is not treated by one doctor but usually a team of 
doctors. The patient has multiple appointments with multiple providers. In some 
clinics, this means going room to room on the same day. In others, it means 
driving to multiple offices over a period of time. Patients can receive mixed 
messaging from multiple providers.  
• It would be helpful to add a question about whether the patient had someone 
who accompanied her to these appointments (like an advocate - someone who 
could help listen and help in decision making). 
• Rather than asking if the patient was “hesitant” to ask questions when talking 
with the providers, ask if the patient felt “comfortable.” 
• The patient may not understand the term “risk score,” so be more general and 
discuss “risk of the cancer coming back.” 
• Patients and providers should take mutual responsibility for the patient’s 
healthcare. Rather than asking questions as if the provider was “doing something” 
to the patient, ask in a more open way such as, “When you were talking about the 
next steps, what came up? What did you and the provider discuss?” versus “Did 
your doctor tell you…” 
• Understand that worry is volatile. The patient’s amount of worry about the 
cancer coming back is probably not the same all the time. Ask about a specific 
point in time. 
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• Be careful with how the conversation is directed in terms of future interventions. 
Do not imply that the patients have made the wrong choice if they have chosen to 
discontinue or not be adherent to the pill taking. 
• Possibly use case scenarios to ask for intervention ideas, or possibly be more 
general and discuss any medication in general. For instance, “Sometimes doctors 
ask us to do things that are difficult/challenging. What are some strategies…?” 
• It may be helpful to note participant body language during the focus groups. 
•Be more general with the conversation. For instance, instead of asking a series of 
pointed questions about the patient/provider interaction, say, “Tell us about your 
first conversation with your provider about taking Tamoxifen. How did it make 
you feel?” 
• Eliminate the participant activities such as having patients come and mark their 
level of worry on a chart. Participants will be more comfortable just responding 
verbally instead. 
Two members from this breast cancer specific Patient Engagement Studio helped 
interpret the focus group results in December 2017. The patient perspective added much 
value to the data analysis process. This meeting was especially helpful to hear ideas from 
the patient perspective on how to practically and concisely organize the results. For 
instance, Table 3.1 below presents the Cues to Action before and after the Patient 




Table 3.1 Cues to action before and after patient engagement studio involvement 
Cues to Action BEFORE Patient 
Engagement Studio Meeting to Analyze 
Focus Group Results 
Cues to Action AFTER Patient 
Engagement Studio Meeting to Analyze 
Focus Group Results 
 Doctor listens to patient, does not 
judge, & does not minimize patient ET 
experience 
 Doctor open to helping lessen side 
effects with holistic approaches and 
switching ET meds 
 Doctor engages with patient as patient 
researches on her own and is part of 
social media platforms & Medical 
community engagement in social media 
outlets 
 Doctor initiates partnership with patient 
in recommending what is best for 
patient (patient desire to be treated as 
an individual – “We are all different”) 
 Doctor openly shares latest ET research 
in patient-friendly manner 
 Doctor is transparent about side effects 
and shares upfront that there are 
possible ways to alleviate potential side 
effects 
 Nutritionist gives personalized dietary 
information based on medications and 
conditions 
 Concept of a “pharmacy home,” 
especially for rural patients 
 Nurse navigator available to discuss the 
cost/benefit analysis of taking ET and 
answer “weird questions”; even better 
if nurse navigator initiates call 
 Staff is friendly, caring, and prompt in 
returning messages 
 Provider listens, does not judge, & does 
not minimize the survivor’s unique, 
individual ET experience 
 Provider is transparent about side 
effects and shares upfront that there are 
possible ways, including holistic 
options, to alleviate potential side 
effects 
 Provider engages with survivor as 
survivor researches on her own and is 
part of social media platforms; provider 
shares latest ET research in patient-
friendly manner 
 Nurse navigator available to discuss the 
risk vs. benefit analysis of taking ET 
and answer “weird questions;” even 
better if nurse navigator initiates call 
 Concept of a “pharmacy home” where 
survivor feels welcomed to ask 
questions 
 Nutritionist gives personalized dietary 






PAPER 1: “ENDOCRINE THERAPY USE IN THE 21ST CENTURY: TEMPORAL 
TRENDS ILLUSTRATE OPPORTUNITIES FOR IMPROVEMENT FOR SOUTH 
CAROLINA MEDICAID WOMEN”  
 
Abstract 
This study examines endocrine therapy (ET) non-initiation, non-adherence, and 
duration by age, race, temporal trend for South Carolina Medicaid-enrolled women 
diagnosed with hormone receptor-positive breast cancer between 2000 and 2014 
(N=3,830). 
Age, race, relative risk and median duration of ET use were compared. Temporal 
trends in ET non-initiation, non-adherence, and duration were observed using linear and 
logistic regression models, controlling for age and race. 
Fifty three percent of women in the sample did not initiate ET, with highest non-
initiation rates among African Americans and survivors under age 50. Of those who did 
initiate ET, 42% were non-adherent with a median ET usage duration of 37 months. 
Twenty one percent of initiators continued taking ET for five years or more. There was 
no change in the odds of ET non-initiation from 2000 – 2004 (OR = 1.02, p = 0.67). The 
odds of ET non-initiation decreased from 2005 – 2009 (OR = 0.81, p < 0.001) but then 
increased from 2010 – 2014 (OR = 1.08, p = 0.002). There was no change in the odds of 
ET non-adherence from 2000 – 2006 (OR = 1.02, p = 0.53), but from 2007 – 2012, the 
odds of ET non-adherence decreased each year (OR = 0.93, p = 0.02). The average ET 
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usage duration was increasing from 2000 – 2006 (β = 2.74, p < 0.001) but decreasing 
from 2006 – 2012 (β = -1.46, p < 0.001). 
This study provides a realistic picture of the challenges associated with ET usage 
among South Carolina Medicaid breast cancer patients. It particularly highlights small 
improvements over time in ET usage rates, indicating more opportunities for 
improvement in ET initiation, adherence, and duration among younger women of lower 
socioeconomic status. 
Introduction 
With advances in breast cancer screening and treatment, the population of female 
breast cancer survivors in the United States continues to grow and was estimated at over 
3.5 million as of January 2016 [1]. This population is expected to total over 4.5 million 
by 2026 [1]. An important issue for female breast cancer survivors is reducing the risk of 
cancer recurrence. The risk of cancer recurrence can be influenced by many factors, 
including the original cancer and the initial treatment.  
Endocrine therapy (ET) has been used for decades as the primary means of 
reducing the risk of breast cancer recurrence and improving disease-free survival in 
women with hormone receptor-positive Stage 0-III disease [2]. However, non-initiation, 
non-adherence, and discontinuation rates remain high [3, 4]. Numerous cross-sectional 
studies have been published highlighting subgroups of women experiencing the highest 
rates of ET non-initiation, non-adherence or discontinuation in certain populations, which 
have often included women younger than age 50 or older than age 70, of African 
American race, and/or of economically disadvantaged populations [5-11]. 
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Even though there has been greater attention given to ET in oncology literature 
and practice [12, 13], a gap persists in the literature regarding how ET usage rates have 
changed over time. There is an impetus to particularly explore longitudinal patterns 
among populations that are known to experience special challenges related to cancer care, 
especially younger and economically disadvantaged women [6, 8, 9, 14]. The purpose of 
this study is to describe ET non-initiation, non-adherence, and duration by age, race, and 
temporal trend for South Carolina Medicaid-enrolled women who had hormone receptor-




South Carolina Central Cancer Registry incidence data from 2000-2014 were used 
to identify the study sample and then linked with South Carolina Medicaid prescription 
claims and administrative data from 2000 through 2016 [15]. The data were linked by 
South Carolina Department of Revenue and Fiscal Affairs using probabilistic match by 
patient first name, last name, Social Security number, and date of birth. Data was de-
identified prior to release to the researchers. Clemson University (IRB2017-133) and 
South Carolina Department of Health and Environmental Control Institutional Review 
Boards approved the study. 
Sample 
This retrospective cohort study included South Carolina (SC) women ages 18-64 
at diagnosis with Stage 0-III or unstaged hormone receptor-positive breast cancer 
diagnosed between 2000 and 2014 (N=34,791). Breast cancer survivors who had SEER 
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summary stage 7 cancer (N=1,531), who did not have estrogen receptor-positive cancer 
(N=5,183), who had prior cancer diagnoses (N=3,016), or whose cancer was identified 
through autopsy or death certificate (N=72) were excluded. After linking with SC 
Medicaid prescription data, breast cancer survivors who did not meet Medicaid eligibility 
inclusion criteria (i.e. no prescription data; N=18,762 or dually enrolled in Medicare; 
N=2,397) were also excluded. Those who were dually enrolled in Medicare were 
excluded because Medicare prescription claims were not available and therefore, ET 
usage could not be reliably tracked. After exclusions, there were 3,830 breast cancer 
survivors included in this study. (Figure 4.1)   
Definition of Non-initiation, Non-adherence, and Duration of ET Usage 
ET was defined as Tamoxifen or one of the following aromatase inhibitors: 
Anastrozole/Arimidex, Letrozole/Femara, or Exemestane/Aromasin, which were 
identified using National Drug Codes from the Medicaid prescription claims. Non-
initiation was defined as not having any Medicaid prescription claims in the entire study 
period (from 2000-2016). The non-initiation rate was calculated by dividing the number 
of women who were ET non-initiators by the total number of eligible women (N=3,830). 
Non-adherence was defined as an ET medication possession ratio of less than 80 percent, 
meaning that the pill supply covered less than 80 percent of the days from the first ET 
prescription dispense date through the last [16]. Duration of ET usage was calculated as 
the number of months between the first and last ET prescription dispense date. The 
proportion of women taking ET for at least 5 years was calculated by dividing the total 
number of women taking ET for at least 5 years by the total number of women initiating 
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ET.  Non-adherence and duration were calculated using the date dispensed and days 
supplied variables from the South Carolina Medicaid pharmacy claims file. 
Statistical Analysis 
Demographic characteristics were compared between ET initiators and non-
initiators using Chi-square tests. Relative risk was calculated for ET non-initiation for 
each of the age/race subgroups, with white/age ≥ 50 years as the reference group.  
ET non-adherence and usage duration analyses were conducted among women 
who had filed at least one ET prescription claim through South Carolina Medicaid and 
who were diagnosed between 2000 – 2012 (N=1,366). Women diagnosed in 2013 and 
2014 were excluded due to the shortened follow-up time since prescription records were 
only available through 2016. Chi-square tests were used to test for a difference in non-
adherence rates among age/race subgroups (i.e. White/age < 50 years, African 
American/age < 50 years, White/age ≥ 50 years, African American/age ≥ 50 years). 
Relative risk of ET non-adherence was calculated for each of the age/race subgroups, 
with White/age ≥ 50 years as the reference group. Kruskal Wallis tests were used to test 
for a difference in median duration of ET usage by age/race subgroups as previously 
defined.  
We also examined temporal trends in endocrine therapy (ET) non-initiation, non-
adherence, and duration. Temporal trend was measured by calendar year of breast cancer 
diagnosis. The objective was to study participants in groups by year of breast cancer 
diagnosis since much of the information and motivation a woman receives for taking ET 
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in the long-term is provided in the initial conversation with a provider when the patient 
receives the first ET prescription.  
We used binary logistic regression to model whether an individual initiated ET or 
not. We also used binary logistic regression to model whether an individual was adherent 
to ET or not. We used ordinary least squares regression to estimate an individual’s ET 
usage duration in months. In each of the three models, we controlled for the covariates 
age (continuous variable centered at the mean) and race (0 = White, 1 = African 
American). 
The data was first examined visually and descriptive statistics were calculated. 
The data did not meet the assumptions for linearity for any of the three outcomes, so non-
linear time trend models were chosen. Non-initiation rates resembled a cubic pattern, so 
the time period was divided into three sub-periods to capture different trends occurring 
during these three sub-periods. Non-adherence and duration seemed to generally increase 
until the year 2006 and decrease thereafter, so time was divided into two sub-periods for 
these analyses. 
To allow for nonlinear changes in ET non-initiation over time, we used a linear 
spline with knots at 2004 and 2009. For non-initiation, we divided time into the periods 
2000 – 2004, 2005 – 2009, and 2010 – 2014. To allow for changes in ET non-adherence 
and duration observed before and after 2006, we used a linear spline with a knot at 2006. 
For non-adherence and duration, we observed changes in the periods 2000 – 2006 and 
2007 – 2012. Wald tests were used to determine whether the coefficients for the different 
time periods were equivalent. Adjusted trends were examined by generating predicted 
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probabilities of ET non-initiation and non-adherence as well as average duration. Stata 




 There were 3,830 Medicaid-eligible women who had hormone receptor-positive 
breast cancer diagnosed between 2000 and 2014 who met the inclusion criteria for this 
analysis. Approximately half of these women (53%, N=2,030) did not fill an ET 
prescription as evidenced by Medicaid prescription claims.  
Demographic characteristics of ET initiators and non-initiators were examined. 
(Table 4.1)  The highest non-initiation rates were seen in African Americans (55% non-
initiation) and survivors under age 50 (56% non-initiation). Compared to White women ≥ 
50, the relative risks for African Americans < 50, White women < 50 and African 
American women ≥ 50 were 1.24 (95% CI: 1.14, 1.36), 1.23 (95% CI: 1.12, 1.34), and 
1.16 (95% CI: 1.05, 1.28), respectively. Non-initiation rates and risk ratios by age/race 
subgroups are presented in Table 4.2. 
Non-Adherence 
Among all initiators, 42% (N=755) of survivors were non-adherent. There was a 
statistically significant difference in the non-adherence rates among the age/race 
subgroups (χ2= 57.91, df = 3, p < 0.001). African American women younger than 50 
years old had the highest non-adherence rates (55%) and were 1.67 (95% CI: [1.43, 
1.95]) times as likely to be non-adherent to ET compared to the most adherent group (i.e. 
 46 
White women age 50 or older). Risk ratios for non-adherence by age/race subgroups are 
presented in Table 4.3.  
Duration 
The median duration of ET usage from 2000 – 2012 was 37 months (Range: 0 – 
184). Twenty-one percent of survivors (N=288) who initiated ET during 2000 – 2012 
continued taking ET for five or more years. Five percent (N=90) only filled one ET 
prescription and did not refill after the first prescription. A Kruskal Wallis test showed 
there was no significant difference in median duration of ET usage by age/race subgroups 
(χ2 = 1.12, df = 3, p = 0.77).   
Temporal Trends 
The non-initiation rates by year of diagnosis are presented in Table 4.4. We found 
a significant difference in the ET non-initiation trends in the three time periods examined 
(χ2(3) = 126.74, p < 0.001). There was no change in the odds of ET non-initiation from 
2000 – 2004 (OR = 1.02, p = 0.67). The odds of ET non-initiation decreased from 2005 – 
2009 (OR = 0.81, p < 0.001) but then increased from 2010 – 2014 (OR = 1.08, p = 
0.002). 
The non-adherence rates and median duration of ET usage by year of breast 
cancer diagnosis are presented in Table 4.5. Results showed that there was a significant 
difference in the ET non-adherence trends before and after 2006 (χ2(2) = 7.01, p = 0.03). 
There was no change in the odds of ET non-adherence from 2000 – 2006 (OR = 1.02, p = 
0.53), but from 2007 – 2012, the odds of ET non-adherence decreased each year (OR = 
0.93, p = 0.02). 
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There was also a significant difference in the ET usage duration trends before and 
after 2006 (F(2, 1361) = 15.51, p < 0.001). The average ET usage duration was 
increasing from 2000 – 2006 (β = 2.74, p < 0.001) but decreasing from 2007 – 2012 (β = 
-1.46, p < 0.001). 
 Figure 4.2 presents the adjusted average probabilities of ET non-initiation and 
non-adherence by year of breast cancer diagnosis as well as the adjusted average ET 
usage duration by year of breast cancer diagnosis. 
 
Conclusion 
This is the first study to use longitudinal data to examine trends in ET non-
initiation, non-adherence, and duration among South Carolina Medicaid-enrolled women. 
Our findings point to several opportunities for further investigation and possible 
intervention.  First, 53% of Medicaid enrollees never initiated treatment. This is of 
concern for multiple reasons. Secondly, when examining the subgroups for possible 
intervention to increase ET adherence, women under 50 years of age, and especially 
African American women under age 50, demand particular attention.  Thirdly, the odds 
of ET non-initiation was increasing from 2010 – 2014 and the average duration of ET 
usage was decreasing from 2007 – 2012.  
There was, however, a significant decline in the odds of ET non-adherence from 
2007 to 2012, and the odds of ET non-initiation had decreased previously in the period 
from 2005 – 2009 with average duration increasing from 2000 - 2006. These positive 
findings are encouraging given the recent attention touting the benefits of ET adherence 
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for women [6]. Because the study spans more than a decade, this data offers one of the 
first long-term assessments of these challenges.  The opportunity is to build on the 
modest positive improvements seen earlier in the past decade. 
Those who initiated ET had a median ET usage duration of 37 months (Range: 0 
– 184), with 21% of initiators continuing ET for five years or more. Given ASCO’s 
recommendations since 2014 to increase ET usage to up to ten years and multiple trials 
showing disease-free survival benefits for those who take ET for 5-10 years [12, 13, 17-
19], it is alarming that only one-fifth of initiators continued for five years or more and 
that the temporal trends showed negative results for the most recent periods concerning 
improvement in individual level ET initiation and duration. 
We found that women under age 50 were less likely to be adherent to ET. These 
findings are consistent with the literature on ET usage [8], which suggests that younger 
women have unique considerations in their ET decision-making framework, including 
fertility [20] and reluctance to believe ET was a necessary part of their breast cancer 
treatment [21]. These explanatory factors are not fully understood and warrant further 
research [22]. 
Some important limitations accompany this analysis. First, we assumed that if a 
person was Medicaid-eligible and did not have a Medicaid pharmacy claim for ET, she 
did not take ET, as there was no other way to document ET received through other 
payment sources. Medicaid recipients do not typically have secondary payment sources 
other than self-pay, so it is not anticipated that significant missed data resulted from this 
limitation. Second, we assumed that if a person filled a prescription, then she took those 
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pills. There was no way to account for whether the women actually took the medication. 
Furthermore, our findings were based on data from the South Carolina Medicaid 
population and may not be generalizable to other populations.  
While promising that rates of non-initiation showed slight yet significant 
decreasing trends and duration showed a slight yet significant increasing trend, these 
results sound a call for greater improvements in ET usage rates among populations of low 
socioeconomic status. More research is needed to decipher potential factors influencing 
slight improvements seen since 2000 in order to capitalize on these efforts to further 
reduce rates of non-initiation and non-adherence and increase duration in the future. 
Moreover, longitudinal analyses among women with private insurance or Medicare are 
warranted to compare changes in ET usage rates over time among these populations. 
Additional analyses should also consider grouping participants by the year corresponding 
to the middle or end of an individual’s ET duration period, where this study chose to 
group participants by year of breast cancer diagnosis. 
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Figure 4.1. Cohort selection criteria 
 
 
Figure 4.2 Adjusted trends in South Carolina Medicaid breast cancer survivors’ 







Table 4.1 Demographic characteristics of South Carolina Medicaid breast cancer 






Race, %       0.025 
     White  50%  53%  
     African American  49%  45%   
Age, %     < 0.001 
     < 50 years old  40%  47%  
     ≥ 50 years old  60%   53%  
Note: The statistical differences were tested using χ2 tests. 
 
Table 4.2 Endocrine therapy non-initiation rates (%) and relative ratios (95% CI) by age 
and race subgroups of South Carolina Medicaid breast cancer survivors 
  Age 
Race Rate < 50 Years ≥ 50 Years 
White 56% 46% 
African American 57% 53% 
 Relative Risk   
 White 1.23 (1.12, 1.34) 1.00 
 African American 1.24 (1.14, 1.36) 1.16 (1.05, 1.28) 
 
Table 4.3 Endocrine therapy non-adherence rates (%) and relative ratios (95% CI) by age 
and race subgroups of South Carolina Medicaid breast cancer survivors 
  Age 
Race Rate < 50 Years ≥ 50 Years 
White 45% 33% 
African American 55% 34% 
 Relative Risk   
 White 1.36 (1.18, 1.63) 1.00 







Table 4.4 Endocrine therapy non-initiation rates among South Carolina Medicaid breast 
cancer survivors by year of diagnosis, 2000 – 2014 








< 50 years 
(N=1,034), % 







All Women in 
Sample 
(N=3,830), % 
2000 66.2 69.2 63.4 61.5 65.3 
2001 75.0 69.4 40.0 65.9 64.0 
2002 69.2 68.1 61.0 73.2 68.2 
2003 73.1 63.0 73.5 66.7 69.2 
2004 64.1 71.1 64.9 74.4 67.3 
2005 53.2 64.7 60.0 57.1 58.3 
2006 52.5 50.0 43.5 74.3 53.4 
2007 50.0 49.2 41.9 56.8 49.0 
2008 58.7 53.7 52.5 50.0 53.4 
2009 47.1 43.2 28.3 38.9 40.7 
2010 41.4 46.2 32.8 38.9 40.3 
2011 45.3 50.7 31.1 48.1 42.6 
2012 55.4 52.5 41.9 47.3 49.5 
2013 49.5 54.5 42.0 37.9 46.0 
2014 58.3 54.3 46.0 39.5 50.1 






Table 4.5 Demographics and endocrine therapy usage non-adherence and duration 


































2000 74 22 16 15 20 46% (34) 20.5 (0 – 
184) 
2001 77 14 22 24 15 47% (36) 22 (0 – 142) 
2002 77 20 29 16 11 47% (36) 30 (0 – 167) 
2003 74 18 27 13 16 50% (37) 23.5 (0 – 
112) 
2004 54 14 13 13 10 44%(24) 21.5 (0 – 
147) 
2005 78 29 18 14 15 50% (39) 34 (0 – 123) 
2006 88 28 23 26 9 50% (44) 49.5 (0 – 
119) 
2007 103 27 33 25 16 47% (48) 46 (0 – 111) 
2008 96 26 25 19 23 47% (45) 39 (0 – 90) 
2009 162 45 42 38 33 42% (68) 46.5 (0 – 
138) 
2010 173 51 42 43 33 42% (72) 41 (0 – 79) 
2011 179 47 36 62 28 34% (61) 45 (0 – 137) 
2012 164 41 38 54 29 38% (62) 39 (0 – 142) 
aSurvivors diagnosed in 2013 and 2014 could only be followed for 48 and 36 months, 
respectively. 
bSample included all female Medicaid recipients ages 18-64 at diagnosis with Stage 0-III or 
unstaged hormone receptor-positive breast cancer diagnosed between 2000 and 2014 who filled at 
least one ET prescription. Survivors with prior cancer diagnoses, who were dually enrolled in 





PAPER 2: “FACTORS ASSOCIATED WITH LONGER ENDOCRINE THERAPY 




Endocrine therapy (ET) discontinuation rates remain high, despite its use for 
decades as the primary means of increasing disease free survival in women with hormone 
receptor-positive Stage 0-III breast cancer. Research informing enhanced intervention 
methods is needed as is research regarding the optimal timing of these interventions. The 
objective of this study is to determine demographic, clinical, and pharmaceutical factors 
that are associated with longer ET usage duration. 
South Carolina Central Cancer Registry incidence data linked with South Carolina 
Medicaid prescription claims and administrative data were used. The study included a 
sample (N=1,399) of female South Carolina Medicaid recipients with hormone receptor-
positive breast cancer diagnosed between 2000 and 2012 who filled at least one ET 
prescription. A series of multiple regression models were built to explore the association 
of demographic, clinical, and pharmaceutical factors with ET usage duration. 
Multiple linear regression analysis showed that none of the demographic or 
clinical factors tested were significantly associated with ET usage duration. However, the 
type of ET taken as well as receipt of the prescriptions that could have been used to 
alleviate side effects (adrenals, nonsteroidal anti-inflammatory agents, anti-inflammatory 
agents, and vitamins) were significantly associated. 
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Our study highlights the potential value of concurrent prescriptions for improving 
ET usage duration, with an optimal intervention point before 14 months post ET 
initiation. Further research is needed to test pharmacologic interventions that may 




Endocrine therapy (ET) has been used for decades as the primary means of 
increasing disease free survival in women with hormone receptor-positive Stage 0-III 
breast cancer, yet discontinuation rates remain high [1, 2]. Murphy et al. (2012) 
conducted a systematic review to examine literature from 1998-2012 related to ET 
adherence and continuation in routine clinical settings.  The percentage of tamoxifen 
users who discontinued treatment ranged from 15–20% in the first year of therapy to 31–
60% at the end of five years [3]. The percentage of aromatase inhibitor users who 
discontinued treatment ranged from 5–25% during the first two years of therapy [3]. 
Studies examining both tamoxifen and aromatase inhibitor users showed discontinuation 
rates between 32-73% by the end of five years of treatment [3]. 
Numerous studies have been conducted to examine factors that contribute toward 
non-adherent, non-persistent ET use. The following subgroups have been highlighted as 
at-risk: low socioeconomic status [4-6], low social support [3, 7-8], greater comorbidity 
[7-8], greater drug cost [3, 7], greater side effects [3, 8], lack of provider communication 
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regarding the importance of ET [3, 8], extremes of age [3, 8], and follow-up care with a 
general practitioner versus a cancer specialist [3, 8].  
As literature has established, the Medicaid population is at high risk for poor ET 
usage [4-6]. Interventions to improve ET usage have been conducted in various 
populations, but there is especially a lack of evidence of how to improve ET usage among 
Medicaid recipients [9-12]. Qualitative studies reveal that side effects, primarily 
menopausal symptoms and/or joint pain, emerge as the major barrier to continuing ET for 
the recommended duration [13-17]. Tested interventions have focused on patient 
education and side effect management, including elements such as educational materials, 
phone or text message reminders, vaginal moisturizers, topical oil for joint pain, and cool 
pad pillow toppers [9, 18-21].  Recent systematic reviews of interventions targeted at 
improving ET usage showed no meaningful improvements over usual care, highlighting 
the urgent need for more effective interventions [9, 21-22]. Medications have been 
recommended to alleviate ET side effects, including alpha-agonist hypertensives, 
antidepressants, anticonvulsants, adrenals, nonsteroidal anti-inflammatory agents,  anti-
inflammatory agents, and vitamins [23-28]. While the most effective methods for 
necessary intervention are still under development, there is also a gap in the literature 
regarding the optimal timing for intervention. The aim of this study is to identify 
demographic, clinical, and pharmaceutical factors that are associated with an individual’s 







The study sample was identified using South Carolina Central Cancer Registry 
incidence data from 2000-2012 linked with South Carolina Medicaid prescription claims 
and administrative data from 2000 through 2016 [29]. Probabilistic match by patient first 
name, last name, Social Security number, and date of birth was used for the linkage 
performed by the South Carolina Department of Revenue and Fiscal Affairs. Data was 
de-identified prior to release to the researchers. Clemson University and South Carolina 
Department of Health and Environmental Control Institutional Review Boards approved 
this study. 
Sample 
The study sample (N=1,399) included all female South Carolina Medicaid 
recipients ages 18-64 at diagnosis with stage 0-III or unstaged hormone receptor-positive 
breast cancer diagnosed between 2000 and 2012 and who filled at least one ET 
prescription. Exclusion criteria were SEER summary stage 7 cancer, estrogen receptor-
negative cancers, prior cancer diagnoses, cancer identification through autopsy or death 
certificate, and dual enrollment in Medicare (since Medicare prescription claim data was 
not available). 
Dependent Variable 
ET included tamoxifen and the following aromatase inhibitors: 
Anastrozole/Arimidex, Letrozole/Femara, or Exemestane/Aromasin. Drugs were 
identified using therapeutic class and National Drug Codes from Medicaid prescription 
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claims. ET usage duration was calculated as the number of months between the first and 
last ET prescription dispense dates using the date dispensed and days supplied variables 
from the South Carolina Medicaid pharmacy claims file. Participants were followed from 
the time of their first ET prescription filled through 2016. 
Independent Variables 
Independent variables included the factors hypothesized to be associated with ET 
usage duration based on literature review. The following demographic, clinical, and 
pharmaceutical factors were examined: 
 Demographic: race (white, African American, or other), age at diagnosis, marital 
status (married/unmarried), and rural/urban residency status (2013 Rural-Urban 
Continuum Codes) 
 Clinical: SEER summary breast cancer stage, receipt of chemotherapy (yes/no), 
and receipt of radiation therapy (yes/no) 
 Pharmaceutical: Type of endocrine therapy (Tamoxifen, Anastrozole/Arimidex, 
Exemestane/Aromasin, Letrozole/Femara, switched between aromatase inhibitors, 
switched between Tamoxifen and aromatase inhibitors), and filled alpha-agonist 
hypertensives prescription (yes/no), filled antidepressants prescription (yes/no), 
filled anticonvulsants prescription (yes/no), filled adrenals prescription (yes/no), 
filled nonsteroidal anti-inflammatory agents prescription (yes/no), filled anti-
inflammatory agents prescription (yes/no), and filled vitamins prescription (B, C, 
D, K, and/or multivitamin) (yes/no). The prescriptions were identified by 
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therapeutic class code and measured as ever having filled prescription during the 
study period as evidenced by Medicaid claims. 
Provider specialty data had a high number of missing values and therefore was not 
included in the study. 
Statistical Analysis 
Multiple linear regression models were built to explore the impact of 
demographic, clinical, and pharmaceutical factors on ET usage duration in months (α = 
0.05). First, a series of models was made by singularly entering each of the independent 
variables with the dependent variable ET usage duration. Then, the combined effect of 
the independent variables that were significantly associated with the dependent variable 
was examined. Interactions terms were generated for each pair of significant independent 
variables and entered as a block to test for significant association with ET usage duration. 
The final model was generated by removing variables from the model that were no longer 
significant when controlling for other factors and adding the significant interaction terms. 
The final model included ET type; receipt of the following concurrent prescriptions: 
adrenals, nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and/or 
vitamins; and ET type/adrenals and anti-inflammatory agents/vitamins interactions. 
StataMP 14.0 was used for all analyses. 
 
Results 
The study sample consisted of 1,399 hormone receptor-positive cancer survivors. 
Fifty-three percent of women in the study sample were white (N=744), and 44% were 
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African American (N=622). The median age at diagnosis was 49 years (Range: 21 – 64). 
Twenty-nine percent (N=376) were single, 36% (N=456) were married, and 16% 
(N=210) were divorced. Following the 2013 Rural-Urban Continuum Codes for South 
Carolina, 79% (N=1,101) of the women resided in metropolitan counties. The breakdown 
by SEER summary breast cancer stage was as follows: Stage 0 (N=164, 12%), Stage 1 
(N=576, 41%), Stage 2 (N=24, 2%), Stage 3 (N=530, 38%), Stage 4 (N=88, 6%), and 
unknown (N=17, 1%). Fifty-three percent (N=743) of the sample had received 
chemotherapy, and 44% (N=612) had received radiation therapy. 
Forty-one percent (N=577) of the women were taking Tamoxifen, and 36% were 
taking aromatase inhibitors (Anastrozole/Arimidex: N=199, 14%, Exemestane/Aromasin: 
N=34, 2%, Letrozole/Femara: N=186, 13%, switched between different aromatase 
inhibitors: N=91, 7%). Twenty-two percent (N=312) of the women switched between 
Tamoxifen and aromatase inhibitors.  
 Eight percent (N=110) had filled a prescription for alpha-agonist hypertensives, 
60% (N=838) had filled a prescription for antidepressants, 32% (N=447) had filled a 
prescription for anticonvulsants, 60% (N=843) had filled a prescription for adrenals, 57% 
(N=801) had filled a prescription for nonsteroidal anti-inflammatory agents, 28% 
(N=386) had filled a prescription for anti-inflammatory agents, and 27% (N=379) had 
filled a prescription for vitamins (B, C, D, K, and/or multivitamins). 
 Multiple linear regression analysis showed that none of the demographic 
or clinical factors tested (race, age at diagnosis, marital status, and rural/urban status, 
SEER summary breast cancer stage, receipt of chemotherapy, receipt of radiation 
 63 
therapy) were significantly associated with ET usage duration. When base models were 
created with each of the pharmaceutical variables and ET usage duration as the dependent 
variable, each of the pharmaceutical variables were significantly associated with ET 
usage duration except Alpha-agonist hypertensives (β = -1.80, p = 0.51). The results are 
shown in Table 5.1 as Models A – G.  
Next, all of the pharmaceutical variables were included in a regression model with 
ET usage duration as the dependent variable. See Table 5.1, Model H. The results showed 
that receipt of antidepressants and anticonvulsants was no longer significantly associated 
with ET usage duration when controlling for the other pharmaceutical variables. These 
variables were removed from the model. Interaction terms were generated between each 
pair of pharmaceutical variables and entered as a block in the model; however, only the 
interactions between ET type/adrenals (β = -2.5, p < 0.001) and anti-inflammatory 
agents/vitamins (β = -9.96, p = 0.04) were significant. The final model was developed 
and included ET type; receipt of the following concurrent prescriptions: adrenals, 
nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and/or vitamins; and 
anti-inflammatory agents/vitamins and ET type/adrenals interactions. See Table 5.2. 
 
Conclusion 
Key Results & Interpretation 
Our study found that none of the demographic or clinical factors examined were 
significantly associated with an individual’s ET usage duration. The sample’s 
socioeconomic and age (<64) homogeneity possibly overwhelmed differences in race, 
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marital status, or rural/urban residency status, or as other studies have shown, side effect 
management may be more impactful than demographic or clinical aspects [13-17, 30].  
Similarly, Friese et al. found that race, SEER stage, worry about recurrence, and 
primary oncology provider were not significantly associated with ET usage in a 
population of Los Angeles County and Detroit metropolitan area breast cancer survivors; 
however, age and taking two or more medications weekly were significantly associated 
with greater ET persistence [31]. Women ages 20-79 were included in the Friese et al. 
study. [31]. Calip et al. also found that in a sample of 40,009 women, increasing 
polypharmacy and pill burden were associated with greater ET adherence, but different 
effects were found depending on the medication class [32]. For example, lipid-lowering 
drugs and antihypertensives were associated with higher adherence, and opioid-
containing analgesics, anxiolytics/antipsychotics, antidepressants, and insulin therapy 
were associated with lower adherence [32]. 
Our study highlights the association between ET usage duration with ET type and 
with other prescriptions that were possibly prescribed for side effect management. The 
final model included ET type and receipt of certain prescriptions, which can be used to 
alleviate common side effects of Tamoxifen and aromatase inhibitors: adrenals, 
nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and vitamins.  
The model showed that the average ET duration was 14 months for women 
meeting the sample inclusion criteria, taking Tamoxifen, and who had not filled a 
prescription for any of the following: adrenals, nonsteroidal anti-inflammatory agents, 
anti-inflammatory agents, and/or vitamins. Taking Anastrozole/Arimidex significantly 
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increased ET usage duration by an average of 12.2 months over the duration for 
Tamoxifen, and taking Letrozole/Femara significantly increased duration by 8.9 months. 
Women who switched between different aromatase inhibitors or between Tamoxifen and 
aromatase inhibitors took ET for an average of 23.6 or 29.3 months longer, respectively, 
than Tamoxifen-only users. Having the following prescriptions was also significantly 
associated with increased ET duration: adrenals (+10.9 months), nonsteroidal anti-
inflammatory agents (+8.5 months), anti-inflammatory agents (+9.9 months), and 
vitamins (+11.24 months). As shown by the interaction terms in Table 2, the results are 
not additive for survivors taking adrenals in combination with Letrozole/Femara, 
switching between aromatase inhibitors, or switching between Tamoxifen and aromatase 
inhibitors; or for survivors taking anti-inflammatory agents with vitamins. 
Study Strengths & Limitations 
The literature contains many studies on subpopulations affected by low rates of 
ET usage. This study helps fill a gap in the literature regarding factors positively 
associated with ET usage duration among the socioeconomically disadvantaged that 
could potentially be used to better emerging interventions. The most effective methods 
for these necessary interventions are still under development, and there is a gap in the 
literature regarding the optimal timing for intervention. This study identifies that 
demographic and clinical factors were not associated with ET usage duration for this 
population; however, ET type and having prescriptions for drugs commonly known to 
alleviate side effects was significantly associated.  
This analysis should be viewed as a hypothesis-generating study and can be used 
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to further investigate the relationship between ET type and other prescriptions taken with 
ET with ET usage duration. The variables significantly associated with ET usage duration 
explain 23% of the variance in ET usage duration among the sample, so further 
investigation is warranted to determine other associated factors. The purpose of the 
additional prescriptions was unknown, so it is also not known if these prescriptions were 
written to specifically alleviate side effects or for other purposes. Next steps would 
include looking at the timing of side effect prescriptions and ET medications. Dosage and 
usage patterns of other prescriptions were also not examined, only that the individual 
filled at least one prescription for the medication during the study period. Furthermore, 
over-the-counter NSAIDS or vitamins could not be accounted for due to the nature of 
Medicaid prescription claims data.   
Generalizability & Future Research 
This study focused on South Carolina Medicaid recipients who were hormone 
receptor-positive breast cancer survivors. The results of this study point to an effective 
point of intervention before 14 months for ET initiators who meet the sample inclusion 
criteria and that ET type and other prescriptions taken by survivors are more important 
for increasing the length of ET duration than the demographic and clinical factors 
examined.  Further research is warranted to test these findings in other populations. 
Further research is also needed to test pharmacologic intervention strategies associated 
with longer ET duration in this study in addition to other non-pharmacologic 
interventions among low income populations [33].  
Interventions aimed at enhancing the ET experience for breast cancer survivors to 
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increase disease free survival and quality of life are an immediate need. The results of 
this study can be seen as an important first step at examining factors associated with 
longer ET usage. 
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Table 5.1 Multiple regression results for variables associated with endocrine therapy usage duration for the South Carolina 
Medicaid population, 2000 - 2012 (models A – H) 
 
 A B C D E F G H 














Type of Endocrine Therapy 
    Anastrozle/Arimidex 
    Exemestane/Aromasin 
    Letrozole/Femara 
    Switched Between AIs 
    Switched Between AIs   














Antidepressants  7.62 
(1.49)** 
     0.75 (1.42) 
Anticonvulsants    8.69 
(1.56)** 
    1.44 (1.49) 
Adrenals    10.96 
(1.48)** 
   5.18 (1.40)** 
Nonsteroidal anti-
inflammatory agents 
    13.49 
(1.44)** 
  8.22 (1.41)** 
Anti-inflammatory agents      13.56 
(1.61)** 
 7.58 (1.52)** 
Vitamins (A, B, C, D, E, K, 
and/or multi) 






























Standard errors are reported in parentheses; AI = Aromatase Inhibitor; *, ** indicates significance at the 95% and 99% level, respectively. 
Type of Endocrine Therapy – Tamoxifen and non-receipt of medications through Medicaid were set as the reference groups for the models. 
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Table 5.2 Multiple regression results for variables associated with endocrine therapy 
usage duration for the South Carolina Medicaid population, 2000 - 2012 (final model) 
 
Variables Coefficient Standard 
Error 
P-value 
Intercept 14.06 1.68 <0.001 
Endocrine Therapy Type – Anastrozole/Arimidex 12.20 3.24 <0.001 
Endocrine Therapy Type – Exemestane/Aromasin 4.63 5.48 0.398 
Endocrine Therapy Type – Letrozole/Femara 8.88 3.02 0.003 
Endocrine Therapy Type – Switched Between AIs1 23.58 5.47 <0.001 
Endocrine Therapy Type – Switched Between 
Tamoxifen & AIs1 
29.27 2.85 <0.001 
Receipt of Adrenals Prescription 10.90 2.04 <0.001 
Receipt of Nonsteroidal Anti-Inflammatory Agents 
Prescription  
8.46 1.38 <0.001 
Receipt of Anti-Inflammatory Agents Prescription 9.91 1.81 <0.001 
Receipt of Vitamins Prescription 11.24 1.80 <0.001 
Endocrine Therapy Type Adrenals 
   Anastrozole/Arimidex 
   Exemestane/Aromasin 
   Letrozole/Femara 
   Switched Between AIs1 



















Anti-Inflammatory Agents Vitamins -7.06 3.13 0.024 
N=1,399; R2 = 0.23; Adj R2 = 0.22 




PAPER 3: “‘WALK A MILE IN MY SHOES’ – BREAST CANCER SURVIVORS’ 
PERSPECTIVES ON THE ENDOCRINE THERAPY EXPERIENCE” 
 
Abstract 
This study aims to understand, from the survivor perspective, modifiable factors 
that have the greatest impact on the likelihood of endocrine therapy (ET) continuation. 
  Twenty-two hormone receptor-positive breast cancer survivors under age 64 who 
had been prescribed ET since 2000 were recruited for participation in focus groups 
conducted in four South Carolina locations. Qualitative data analysis was completed by a 
three-member research team using an inductive narrative approach with input from a 
breast cancer survivors’ panel at a local hospital. Themes were examined by participant 
decision to continue or discontinue ET. Quotations exemplifying each theme are provided. 
  Participants’ feedback centered on a risk vs. benefit analysis unique to the 
individual survivor. Main themes included the importance of an open, honest 
patient/provider relationship and the need for personal information seeking and 
affirmation in the decision to take ET. There was clear support for the utility of 
multidisciplinary cancer care teams and incorporating integrative approaches.  
  This study highlights key elements that can be incorporated in interventions to 
enhance the endocrine therapy experiences for breast cancer survivors, with the goal of 
informing improvement in supportive therapy and care. The few studies that have 
addressed currently used interventions to improve adherence showed little to no 
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improvement over usual care. Research employing patient-centered perspectives is 
imperative. Novel and practical patient-centered interventions in research exploring 
openness in the patient/provider relationship, survivor information seeking practices, 
multidisciplinary teams, and integrative approaches are needed. 
 
Introduction 
Following surgery, radiation therapy, and/or chemotherapy, a woman with Stage 
I-III hormone receptor-positive breast cancer is typically prescribed endocrine therapy 
(ET) for five years or longer [1, 2]. The purpose of ET is to reduce a woman’s risk of 
breast cancer recurrence. Taking ET (Tamoxifen or an aromatase inhibitor) as prescribed 
for five years can reduce the risk of recurrence by 40% and death by one-third [3].  
Research and clinical practice confirm that rates of ET are quite low [4-6]. A 
systematic review by Murphy et al. (2012) showed that discontinuation ranged from 31–
73%, measured at the end of 5 years of treatment [7]. ASCO and the National 
Comprehensive Cancer Network currently recommend that women with Stage I-III breast 
cancer take Tamoxifen, an aromatase inhibitor, or a combination of the two types of 
endocrine therapies for up to ten years [1, 8-9].  
Knowledge of the population affected by ET early discontinuation in South 
Carolina (SC) is limited, as is knowledge of how to improve the ET experience for 
survivors.  The few studies that have addressed interventions showed limited to no 
improvement over usual care and have included elements such as educational materials, 
reminder notifications, acupuncture, and vaginal moisturizers [10-12]. This qualitative 
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study aims to understand from the survivor perspective which modifiable factors could 
have the greatest impact on the likelihood of ET continuation. 
 
Methods 
A qualitative study utilizing focus groups of breast cancer survivors was 
conducted. Four focus groups were held between June and October 2017 in four SC 
towns. This research was approved by the Greenville Health System and Clemson 
University Institutional Review Boards. 
In addition, this qualitative study has been informed and guided by the input of a 
general Patient Engagement Studio and a breast cancer specific Patient Engagement 
Studio. The Studio provided recommendations for patient recruitment, raised potential 
survivor concerns, and offered valuable suggestions focus group guide revisions and 
results interpretation.  
 
Recruitment 
Breast cancer survivors were recruited through breast cancer support groups and 
advocacy organizations and a local cancer survivorship institute. Targeted inclusion 
criteria were female, English speaker, diagnosed with Stage I-III hormone receptor-
positive breast cancer since 2000, completed breast cancer treatment, and prescribed 
endocrine therapy between the ages of 18-64 years. 
Project staff contacted potential participants through flyer invitation. Interested 
participants contacted a research project staff member as directed by the flyer, were 
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screened by phone or e-mail, and were assigned to a focus group based on location. 
Participants were incentivized with $50 gift cards. 
Data Collection 
The focus groups lasted approximately 1.5 hours each and were held in neutral, 
private locations. All focus groups were conducted in English by two trained members of 
the project staff. Participants received an informational letter at the beginning of the focus 
group introducing them to the potential benefits and risks of the study. The moderators 
used a focus group guide developed by the research team members with qualitative, 
cancer-focused research experience after reviewing the existing literature to elicit 
participants’ experiences with ET. The guide was driven by elements of the Health Belief 
Model, specifically probing about perceived susceptibility to and seriousness of breast 
cancer recurrence, perceived benefits and barriers to ET continuation, and cues to action 
that may support or encourage ET continuation [13]. The various probes stimulated 
discussion about specific events and experiences that shaped participants’ opinions and 
attitudes regarding ET usage. (See “Focus Group Guide” in Supplementary Materials.) 
Each focus group was audio-recorded and then transcribed by a reputable medical 
transcription service and verified by a member of the project staff. The group 
demographics were obtained via survey. 
Data Analysis 
Data analysis was completed by three members of the research team with input 
from a breast cancer survivors’ panel. The team used a grounded theory approach to 
identify themes and an inductive narrative approach to data analysis [14-17]. The team 
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members began by analyzing one of the focus group transcripts to create a codebook.  
The codebook was expanded as the other three transcripts were analyzed. The analysis 
team followed a process detailed by Miles and Huberman [18], dividing the coding duties 
so that each transcript was coded by at least two independent coders. The team met 
during the coding process to address consensus, update the coding structure, and revisit 
any previously coded text as needed. Codes were applied to transcripts using Atlas.ti 
software Version 7.5.10 [19].  
Themes emerged during a subsequent review and analysis of code based queries 
using the Atlas.ti software. A priori codes drawn from the focus group guide, as informed 
by the Health Belief Model served as the organizing analysis framework. As new themes 
emerged, the narrative was expanded. Two survivors who were not focus group 
participants assisted with identifying themes and expanding the narrative. There were 
fifteen final codes. Themes were examined by participant decision to continue or 
discontinue ET, and quotations exemplifying each theme are provided. 
 
Results 
There were 22 total participants. Participants were a median age of 52 when first 
prescribed ET (Range: 37– 63 years). Sixty-four percent were Caucasian, 23% were 
African American, and 14% were of other race. Participants varied by highest education 
attained: 18% high school diploma, 14% associates’ degree, 41% bachelors’ degree, 18% 
post-baccalaureate degree, and 9% preferred not to answer. Seventy-seven percent had 
private insurance, 9% were on Medicaid, 5% were on Medicare, and insurance type was 
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unknown for 9% of the group. Fifty percent were prescribed Tamoxifen, 41% were 
prescribed aromatase inhibitors, and 9% switched between Tamoxifen and aromatase 
inhibitors. Five participants (approximately 23%) had discontinued ET. Two of the 17 
who continued ET said they had taken a break of at least six weeks before deciding to 
continue again. Table 1 provides more detail on participants’ ET usage. (See Table 6.1.)  
The Health Belief Model was chosen to summarize the survivors’ responses, as 
the women’s perceived susceptibility to breast cancer recurring and perceived 
seriousness/severity of that event influenced the perceived threat of breast cancer 
recurrence, which influenced the likelihood of a survivor continuing endocrine therapy. 
Informed by various sources, survivors’ perceptions of endocrine therapy’s benefits and 
barriers also influenced the likelihood of a survivor continuing ET. (See Figure 6.1.) The 
five main themes that emerged from the analysis are described below. 
Risk vs. Benefit Analysis 
Across the four focus groups, discussion centered on the perceived risks vs. 
perceived benefits that respondents felt was unique to the individual and could not be 
generalized by providers. Continuers and discontinuers alike had experienced many side 
effects that affected quality of life and were the major barrier to continuing ET. These 
included joint pain, bone pain, muscle aches, depression, weight gain, eye problems, 
anger, personality changes, hot flashes, lack of energy, vaginal dryness, and painful sex. 
Many women said that taking the medication made them feel “like a 90 year old.” Most 
discontinuers made statements such as “I just couldn’t take this anymore” and decided to 
focus on quality of life, believing that ET’s benefits did not outweigh its harms. Some 
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discontinuers said their decision was influenced by a low recurrence risk score given by a 
healthcare provider. The majority of discontinuers expressed understanding of their risk 
but were very keen to incorporate dietary changes and supplements to improve overall 
health instead of taking ET. Continuers largely expressed that they were weathering the 
ET experience, though difficult for most, primarily due to fear of recurrence and not 
wanting to have “regrets.” See Table 6.2. This risk vs. benefit analysis did not occur at 
one time point and the decision to continue was not permanent. Participants alluded to 
often re-evaluating their reduction in quality of life due to ET vs. ET’s benefit in reducing 
recurrence risk often through conversations with the provider, husband, or other survivor, 
and/or seeking online information. 
Patient/Provider Relationship 
The patient/provider relationship carried great significance in a survivor’s 
decision to continue or discontinue ET. Survivors valued a provider who transparently 
provided information about the purpose, benefits, and side effects of ET and ways side 
effects may be alleviated. There were mixed opinions among survivors as to how much 
information was “enough” regarding side effects. Some participants wanted to know any 
possibilities upfront saying they would rather be “forewarned,” whereas other survivors 
said being given too much information upfront was frightening and overwhelming: 
If I have one, then I don’t say, ‘Oh my gosh, what’s wrong here?’  Okay, that 
might be a side effect from this because it’s a new medication I’m taking.  It’s 
kind of nice to be forewarned. 
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All survivors agreed that they desired a provider who listened to their concerns 
and was not judgmental in minimizing the side effects a survivor experienced. Survivors 
often made remarks such as, “We know our bodies because we live in them” and wanted 
to be heard by providers. A continuer related her experience with a supportive provider: 
You can be totally blunt with him. And he just really wants to help do what’s best 
for you, but he listens to your issues.  He doesn’t minimize how you’re feeling. 
Several discontinuers indicated that their providers still think the survivors are 
taking ET, and the survivors were not planning to inform the providers otherwise, 
agreeing that they did not want to have to “argue.” Continuers said they valued 
supportive providers’ willingness to help alleviate side effects by switching ET 
medications and/or offering integrative approaches such as exercise, dietary changes, and 
herbs. Some continuers reported changing providers to find someone that could support 
them in this way. Many continuers reported continuing ET simply because it was their 
providers’ recommendation, and they trusted their providers. 
Information Seeking 
The term “research” repeatedly surfaced in all four of the focus groups and among 
both continuers and discontinuers. Participants were probed regarding their information 
seeking behaviors. All groups expressed an understanding for the need to be cautious 
with online research: 
You have to take it with a grain of salt. There are a lot of blogs out there that are 
just really misinformed completely.  And you have to read it sort of weigh it…with 
your oncologist and sort of figure it out.   
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Participants also appreciated their cancer clinic or provider supplying links to 
reputable sources.  In addition to specific sites mentioned (e.g. Mayo Clinic and 
American Cancer Society), participants also expressed an affinity for joining either online 
or in-person discussion groups of breast cancer patients and survivors, citing that the 
groups had been a very supportive place to ask questions, seek advice, and be encouraged 
by women who understood what they were going through. Some participants found 
groups very comforting and what they described as the best source of information 
because the information shared by other survivors is “experiential.” Still others expressed 
a desire to be more private about their care and seek information only from medical 
professionals.  
Some participants related that their providers were dismissive when survivors 
mentioned the topic of joining online communities or researching information on their 
own. Providers cautioned the women that they should not become part of such 
communities for fear of the survivors becoming misinformed, which was described by a 
discontinuer as “insulting” and “frustrating.” One continuer related a more positive 
experience of chatting with other survivors online and learning about a medication that 
had helped alleviate hot flashes for a woman in another state. After sharing the woman’s 
experience with her provider, the provider prescribed the medication, consequently 
helping the woman and allowing her to continue ET.  
Multidisciplinary Cancer Care Teams 
There was clear support for the utility of multidisciplinary cancer care teams. The 
roles of nurse navigator, rural pharmacist, and nutritionist were specifically highlighted. 
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Survivors whose cancer clinics had a nurse navigator differed in their opinion on the role. 
All agreed it was comforting to have the nurse navigator’s phone number in case “you 
have one of those weird questions.” However, many said it would have been very helpful 
for the nurse navigator to have made an introductory contact. One survivor summarized 
her experience in deciding whether to take ET and how the nurse navigator could have 
assisted: 
I’m sure she could have helped me a great deal because I was panicking going, 
do I do this, do I not do this, you know, talking into my head and I didn’t want to 
really talk it out to everybody else, because I didn’t want to hear everybody else’s 
opinion. You know, because their opinion may not be in my best interest, but 
they’re just going on what other people did. I really wanted somebody 
knowledgeable. 
Many participants said that they did not have any regular contact with a 
pharmacist; however, in the most rural focus group location, the local pharmacist was 
highlighted and discussed as a key source of trusted information for the participants. 
Participants related instances of asking the pharmacist questions, saying “They will take 
the time to talk with you.” and “What a blessing to have her!” Establishing trusting 
relationships with pharmacists and these other mentioned allied health professionals was 
reported as beneficial to survivors. 
Integrative Approaches 
Both continuers and discontinuers overwhelmingly expressed a desire for more 
integrative approaches to help alleviate the side effects of ET and improve overall health. 
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Some described providers who were excellent in sharing these options with survivors, 
whereas others were frustrated with the lack of assistance they were receiving from 
providers in this area. Many survivors discussed trying dietary modifications such as 
excluding soy, sugar, grapefruit, and meat or including more fruits and vegetables, 
turmeric, Calcium, Vitamin B, Vitamin C, Vitamin D and lemon drops in addition to 
lifestyle changes such as more physical activity, less stress, yoga, and mindfulness. A 
participant summarized the resounding call for these options as follows: 
What we feel with the medical establishment is all they know is drugs and they cut 
people and they dope people.  We hear all the time, and most people are 
educating themselves, but there’s all kinds of other healthy, exercise, diet, all 
those things that you can do.  But medical providers don’t do a whole lot to help 
you with that or point you in the right direction.   
Some participants were survivors at cancer clinics that offered nutrition 
counseling but were not pleased with the services, saying that the information they had 
received was the “same old, same old.” Nutrition and dietary change was of great 
interest. Participants expressed a desire for more individualized counseling rather than 
rather than generalized, elementary nutrition information.  
 
Conclusion 
ET discontinuation rates remain high despite the use of ET for decades as the 
primary means of reducing the risk of breast cancer recurrence in women with hormone 
receptor-positive Stage I-III disease [3, 20]. Existing studies have examined variables 
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associated with ET continuation and adherence or address patient reported barriers but 
highlight a gap in understanding from the patient perspective which modifiable factors 
could improve the ET experience for patients [21-24].  
In our qualitative study, we found clear survivor support for an open, honest, 
ongoing patient/provider relationship, support for personal information seeking and 
affirmation for continual ET risk vs. benefit re-evaluation, and multidisciplinary cancer 
care teams that can provide integrative approaches to supplement conventional care. 
There were several issues raised regarding the risk vs. benefit analysis that participants 
felt was unique to the individual and could not be generalized by providers. Participant 
feedback provided clear support for patient-centered and individualized cancer care.  
These findings were consistent with other qualitative studies conducted among 
similar populations. Van Londen et al. reported that women view taking ET as something 
necessary for their health but re-evaluate the decision to take ET due to unanticipated side 
effects [25]. Discussing these side effects with providers, family, and others was difficult, 
and women were dissatisfied overall with the side effect symptom management 
information and strategies available [25]. In addition, Pellegrini et al. similarly found that 
women shared the distress and tension they felt while taking Tamoxifen because of the 
paradoxical situation that the drug’s purpose was to save life but it was causing their 
youthful looks and femininity to diminish [26]. 
One strength of our study is that it provides unique comparisons between the 
opinions and concerns of ET continuers and discontinuers. While novel and informative 
for hypothesis generation, a major limitation of this study is that the findings cannot be 
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generalized to all breast cancer survivors, since the majority of women in the sample 
were in the 40 to 50’s age group, above the state’s average education level, and proactive 
toward their health and wellness. There was repetition in themes, indicative of saturation, 
so we believe the sample was large enough to capture the most important opinions and 
concerns of SC breast cancer survivors taking ET. 
The knowledge gained from these focus groups is critical to guide future 
development of interventions aimed at increasing ET continuation in this population. 
Most notably, researchers and clinicians must consider how to address survivor concerns 
regarding a more open, honest, ongoing two-way discussion between survivors and their 
providers. Consistent with other studies of breast cancer survivors’ preferences, our study 
showed that it may be helpful to employ a shared decision making model as the standard 
of care when approaching the concept of endocrine therapy continuation and 
modification of breast cancer recurrence risk factors, as is already being implemented for 
initial breast cancer diagnosis and treatment [27-29]. As recommended by Charles, Gafni, 
and Whelan (1997), shared decision making includes that 1) both the physician and 
patient are involved, 2) both parties share information, 3) that both parties take steps to 
build a consensus about the preferred treatment, and 4) that an agreement is reached on 
the treatment to implement [30]. 
Survivors expressed a strong desire to make their own decisions with information 
and guidance from their providers, consistent with the findings of Wells et al. [31]. Some 
survivors indicated they were not able to have honest conversations about ET with their 
providers. Others alluded to feeling condemned when trying to raise the issue of side 
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effects or information found online or from other women. In order for a shared decision 
making model to be implemented more effectively, it may be useful to train breast cancer 
survivors to more assertively communicate with their providers, as has been effective 
with other patient populations [32]. Likewise, the principles and practice of shared 
decision-making should continually be incorporated in medical education and oncology 
residency training programs.  
Another main topic in patient/provider communication centered on discussions of 
patient information seeking. Our study showed that survivors whose doctors criticized or 
dismissed the online information they presented were more likely to follow advice from 
other sources or go against the doctor’s advice possibly due to this perceived dissonance. 
Tan and Goonawardene (2017) conducted a systematic review of Internet Health 
Information Seeking and the Patient-Physician Relationship [33]. Similar to accounts 
reported by some of the survivors in our study, this systematic review showed that some 
survivors felt physicians avoided online information-related dialogues in order to reclaim 
the traditional, authoritarian consultation model. Tan and Goonawardene affirm the 
importance of allowing or encouraging survivors to discuss their online information 
searches with physicians [33]. Their findings showed that survivors mainly used the 
internet to be actively involved in decision making related to their health (i.e. preparing 
for visits, asking better questions, better understanding information from physicians) but 
still very much trusted their physicians and valued their consultations. This finding offers 
a specific opportunity to provide patient centered care: provider’s recognition of a 
patient’s efforts in the self-education process. 
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The systematic review findings showed these information seeking behaviors 
actually empowered survivors to play a more active role in their disease management, to 
become more effective in understanding and communicating with their physicians, and to 
be more confident in and comfortable with their physicians’ advice. In addition, as Falisi 
et al. (2017) reported in a systematic review of breast cancer survivors’ use of social 
media, more study is needed to better understand social media engagement and content to 
psychosocial, behavioral, and physical health outcomes and how best to leverage social 
media to meet these needs [34].  
The utility of multidisciplinary oncology teams that can incorporate integrative 
approaches was highlighted in the focus groups. Some survivors had benefitted from care 
by such teams while others had not. Multidisciplinary cancer care can be defined as a 
“deliberately designed system that creates a common communication platform among 
different providers of cancer care, enabling complex decision making and resulting in a 
tailored individual management plan” [35]. The need for multidisciplinary care arose 
from survivors feeling overwhelmed and confused after being transferred between 
clinicians at various stages of diagnosis and treatment without an integrated approach 
[36]. While existing multidisciplinary teams may typically be physician-led, our study 
shows that it may be helpful to also include allied health professionals such as 
pharmacists, nurse navigators, and nutritionists who may be working directly with the 
patient over the course of five to ten years and can provide more individual counsel and 
information related to integrative approaches as survivors continually re-evaluate the 
decision of whether to continue ET [37]. Incorporating these individuals as part of the 
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care team may also help improve the continuity of care, especially throughout the cancer 
survivorship journey. Multidisciplinary teams that include allied health professionals and 
nurse navigators align with the transition to a more patient-centered approach in cancer 
care, in which increasing emphasis is placed on a survivor’s overall well-being and 
quality of life, and survivorship [38-39]. 
As breast cancer survivors become an increasingly larger population, there is 
imminent need for novel patient-centered interventions to enhance the ET experience. 
This research and other patient-centered approaches are increasingly valuable in 
providing insight into survivor care needs and perceptions, with a goal of ensuring that 
cancer survivors have an opportunity for the most comprehensive and highest quality 
cancer care possible.   
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Figure 6.1 Health belief model for endocrine therapy usage to reduce risk of breast 






















Table 6.1 Participant endocrine therapy usage characteristics (N=22)  
 Frequency (%) 
Breast Cancer Stage at Diagnosis 
     0* 1 (5%) 
     I 10 (45%) 
     II 6 (27%) 
     III 4 (18%) 
     IV* 1 (5%) 
Type of Endocrine Therapy 
     Tamoxifen 11 (50%) 
     Aromatase Inhibitor 9 (41%) 
     Switched from Tamoxifen to Aromatase Inhibitor  2 (9%) 
Endocrine Therapy Continuation 
     Plans to Continue Endocrine Therapy for Recommended 
Duration 
17 (77%) 
     Declined or Discontinued Endocrine Therapy 5 (23%) 
 Median (Range) 
Years on Tamoxifen 
     All Participants 2.5 (0 – 5) 
     Participants who Plan to Continue 3.7 (1.5 – 6) 
     Participants who Declined or Discontinued 0 (0 – 0.8) 
Years on Aromatase Inhibitor 
     All Participants 2 (0 – 10) 
     Participants who Plan to Continue 3.3 (1-10) 
     Participants who Declined or Discontinued 0.6 (0 – 0.1) 
*While Stage I-III was the target group for recruitment, one participant was Stage 0, and 
one participant was Stage IV.
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Table 6.2 Sample quotes exemplifying participant perceptions regarding susceptibility 




 I feel like if it comes back it’s not 
because I’m not doing everything I 
was supposed to do.” 
 “You feel like an 80-year-old woman 
in the mornings sometimes, but I 
have to have a security blanket.” 
 “It’s bones and joints and all that, but 
I just feel like I want to do everything 
that I can because if it were to come 
back, I am a guilty person…I should 
have done this or I should have done 
that. This way, if it does come back, 
okay, I’ve done everything I can and 
it’s in God’s hands.” 
 “There really aren’t alternatives…I 
want to be here. I’ve got little kids; I 
will do it.” 
 “My mom regretted not doing 
treatment.” 
 “Many went before us young.” 
 “I don’t have any family history of 
breast cancer, so it wasn’t something 
that I was worried about as far as a risk 
factor.” 
 “If cancer’s gonna take me out, then let 
cancer take me out. I’m not doing these 
drugs. I don’t like to take drugs. I took 
it a couple of days and it just made me 
feel so bad until I decided this is not it. 
If the Lord is ready for me, I’m going 
home, but in the meantime, I was 
telling my story. Letting other people 
know, because folks were just afraid of 
cancer.” 
 “My doctors says without anything, the 
difference is 3%. So, at my highest, it 
would be like 16% recurrence. And I 
said you know, I’m just at a point in 
my life where I’m not worried about 
getting cancer again. I’m not worried 
about my body. My quality of life is 


















Overview of Study Findings and Strengths 
This dissertation work had three major aims: 1) To describe ET non-initiation, 
non-adherence, and duration by age, race, and temporal trend, 2) To identify demographic, 
clinical, and pharmaceutical factors that are associated with an individual’s ET usage 
duration, and 3) To understand from the survivor perspective which modifiable factors 
could have the greatest impact on the likelihood of ET continuation. These aims were 
achieved by a convergent parallel mixed methods research study. The answers to each of 
the research questions are summarized Table 7.1. 
Table 7.1 Summary of research aims, questions, hypotheses, and results 
Research Question Hypothesis Results 
AIM #1 To describe ET non-initiation, non-adherence, and duration by age, race, and 
temporal trend 
#1 How do rates of ET 
non-initiation, non-
adherence, and 




duration rates are 
worse among younger 
women and women of 
African American 
race. 
53% of Medicaid enrollees never initiated 
treatment. 21% of initiators continued ET 
for five years or more, with a mean and 
median of 37 months. African American 
women under age 50 had the lowest rates of 
non-initiation and non-adherence. There was 
no significant difference in median duration 
of ET usage by age/race subgroups 




during the study 
period? 
There has been no 
change over the study 




There was a significant decline in the odds 
of ET non-initiation from 2005 – 2009 but a 
significant increase from 2010 – 2014. Non-
adherence decreased from 2007 – 2012. 
Average duration of ET usage increased 
from 2000 – 2006 but decreased from 2007 
– 2012.  
AIM #2 To identify demographic, clinical, and pharmaceutical factors that are associated 





factors are associated 
with an individual’s 
ET usage duration? 
 
Women taking 
Tamoxifen will have 
lower ET usage 
duration than women 
taking aromatase 
inhibitors. Filling 
prescriptions for drugs 
known to alleviate side 
effects will increase 
ET usage duration. 
None of the demographic or clinical factors 
examined were significantly associated with 
an individual’s ET usage duration. The final 
model showed the following were 
significantly associated with longer ET 
usage duration: type of ET and receipt of 
prescription for the following medications: 
adrenals, nonsteroidal anti-inflammatory 
agents, anti-inflammatory agents, and 
vitamins. 
AIM #3 To understand from the survivor perspective which modifiable factors could have the 
greatest impact on the likelihood of ET continuation. 
#4 What are women’s’ 
perceptions regarding 
susceptibility/severity 
of breast cancer 
recurrence? 
Women’s 
susceptibility to breast 
cancer recurrence will 
be influenced by 
provider-patient 
communication. 
Women will perceive 
recurrence as severe 
but also be influenced 
by short-term quality 
of life preferences. 
Continuers “just want to live” and are 
fearful of regret/guilt if cancer recurs 
 
Discontinuers emphasize importance of 
quality of life; cite low risk score, no family 
history, and/or not afraid of cancer or death 
 
#5 What are the 
perceived 
benefits/barriers to ET 
continuation? 
Side effects will 
emerge as a major 
perceived barrier to ET 
continuation. 
Benefits: Understanding that endocrine 
therapy reduces estrogen levels which feed 
ER+ breast cancer 
 
Barriers: Side effects, drugs are 
toxic/harmful 
#6 What are the cues 
to action that 




play a key role in 
supporting ET 
continuation. 
 Provider listens, does not judge, & does 
not minimize the survivor’s unique, 
individual ET experience 
 Provider is transparent about side effects 
and shares upfront that there are possible 
ways, including holistic options, to 
alleviate potential side effects 
 Provider engages with survivor as 
survivor researches on her own and is 
part of social media platforms; provider 
shares latest ET research in patient-
friendly manner 
 Nurse navigator available to discuss the 
risk vs. benefit analysis of taking ET and 
 97 
answer “weird questions;” even better if 
nurse navigator initiates call 
 Concept of a “pharmacy home” where 
survivor feels welcomed to ask 
questions 
 Nutritionist gives personalized dietary 




This is the first study to use longitudinal data to examine trends in ET non-
initiation, non-adherence, and duration among South Carolina Medicaid-enrolled women. 
Our findings point to several opportunities for further investigation and possible 
intervention.  First, 53% of Medicaid enrollees never initiated treatment. This is of 
concern for multiple reasons. Secondly, when examining the subgroups for possible 
intervention to increase ET adherence, women under 50 years of age, and especially 
African American women under age 50, demand particular attention.  Thirdly, the odds of 
ET non-initiation was increasing from 2010 – 2014 and the average duration of ET usage 
was decreasing from 2007 – 2012.  
There was, however, a significant decline in the odds of ET non-adherence from 
2007 to 2012, and the odds of ET non-initiation had decreased previously in the period 
from 2005 – 2009 with average duration increasing from 2000 - 2006. These positive 
findings are encouraging given the recent attention touting the benefits of ET adherence 
for women (Hershman et al., 2011). Because the study spans more than a decade, this data 
offers one of the first long-term assessments of these challenges. The opportunity is to 
build on the modest positive improvements seen earlier in the past decade.  
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Those who initiated ET had a median ET usage duration of 37 months (Range: 0 – 
184), with 21% of initiators continuing ET for five years or more. Given ASCO’s 
recommendations since 2014 to increase ET usage to up to ten years and multiple trials 
showing disease-free survival benefits for those who take ET for 5-10 years (Helwick, 
2016; Goodman, 2017; Burstein et al., 2014; “ASCO Guideline Update,” 2014; 
“Hormonal Therapy for Early-Stage,” 2016), it is alarming that only one-fifth of initiators 
continued for five years or more and that the temporal trends showed negative results for 
the most recent periods concerning improvement in individual level ET initiation and 
duration. 
We found that women under age 50 were less likely to be adherent to ET. These 
findings are consistent with the literature on ET usage (Murphy et al., 2012), which 
suggests that younger women have unique considerations in their ET decision-making 
framework, including fertility (Rosenberg & Partridge, 2015) and reluctance to believe ET 
was a necessary part of their breast cancer treatment (Walker et al., 2016). These 
explanatory factors are not fully understood and warrant further research (Wassermann et 
al., 2017). 
Our study also found that none of the demographic or clinical factors examined 
were significantly associated with an individual’s ET usage duration. The sample’s 
socioeconomic and age (<64) homogeneity possibly overwhelmed differences in race, 
marital status, or rural/urban residency status, or as other studies have shown, side effect 
management may be more impactful than demographic or clinical aspects (Wagner et al., 
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2018; Paul, 2011; Bluethmann et al., 2017; Wheeler et al., 2016; Wells et al., 2016; Felder 
et al., 2016).  
Our study highlights the association between ET usage duration with ET type and 
with other prescriptions that were possibly prescribed for side effect management. The 
final model included ET type and receipt of certain prescriptions, which can be used to 
alleviate common side effects of Tamoxifen and aromatase inhibitors: adrenals, 
nonsteroidal anti-inflammatory agents, anti-inflammatory agents, and vitamins.  
The literature contains many studies on subpopulations affected by low rates of ET 
usage. This study helps fill a gap in the literature regarding factors positively associated 
with ET usage duration among the socioeconomically disadvantaged that could potentially 
be used to better emerging interventions. The most effective methods for these necessary 
interventions are still under development, and there is a gap in the literature regarding the 
optimal timing for intervention. This study identifies that demographic and clinical factors 
were not associated with ET usage duration for this population; however, ET type and 
having prescriptions for drugs commonly known to alleviate side effects was significantly 
associated.  
In our qualitative study, we found clear survivor support for an open, honest, 
ongoing patient/provider relationship, support for personal information seeking and 
affirmation for continual ET risk vs. benefit re-evaluation, and multidisciplinary cancer 
care teams that can provide integrative approaches to supplement conventional care. There 
were several issues raised regarding the risk vs. benefit analysis that participants felt was 
unique to the individual and could not be generalized by providers. Participant feedback 
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provided clear support for patient-centered and individualized cancer care. A major 
strength of the qualitative study is that it provides unique comparisons between the 
opinions and concerns of ET continuers and discontinuers. 
 
Limitations 
Some important limitations accompany this analysis. First, we assumed that if a 
person was Medicaid-eligible and did not have a Medicaid pharmacy claim for ET, she 
did not take ET, as there was no other way to document ET received through other 
payment sources. Medicaid recipients do not typically have secondary payment sources 
other than self-pay, so it is not anticipated that significant missed data resulted from this 
limitation. Second, we assumed that if a person filled a prescription, then she took those 
pills. There was no way to account for whether the women actually took the medication. 
Furthermore, our findings were based on data from the South Carolina Medicaid 
population and may not be generalizable to other populations.  
This study should be viewed as a hypothesis-generating study and can be used to 
further investigate the relationship between ET type and other prescriptions taken with 
ET with ET usage duration. The variables significantly associated with ET usage duration 
explain 23% of the variance in ET usage duration among the sample, so further 
investigation is warranted to determine other associated factors. The purpose of the 
additional prescriptions was unknown, so it is also not known if these prescriptions were 
written to specifically alleviate side effects or for other purposes. 
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While novel and informative for hypothesis generation, a major limitation of the 
qualitative portion of this study is that the findings cannot be generalized to all breast 
cancer survivors, since the majority of women in the sample were in the 40 to 50’s age 
group, above the state’s average education level, and proactive toward their health and 
wellness. There was repetition in themes, indicative of saturation, so we believe the 
sample was large enough to capture the most important opinions and concerns of SC 
breast cancer survivors taking ET. 
 
Future Work 
While promising that rates of non-initiation showed slight yet significant 
decreasing trends and duration showed a slight yet significant increasing trend, these 
results sound a call for greater improvements in ET usage rates among populations of low 
socioeconomic status. More research is needed to decipher potential factors influencing 
slight improvements seen since 2000 in order to capitalize on these efforts to further 
reduce rates of non-initiation and non-adherence and increase duration in the future. 
Moreover, longitudinal analyses among women with private insurance or Medicare are 
warranted to compare changes in ET usage rates over time among these populations. 
Additional analyses should also consider grouping participants by the year corresponding 
to the middle or end of an individual’s ET duration period, where this study chose to 
group participants by year of breast cancer diagnosis. 
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Next steps also include looking at the timing of side effect prescriptions and ET 
medications. Dosage and usage patterns of other prescriptions were also not examined, 
only that the individual filled at least one prescription for the medication during the study 
period. Furthermore, over-the-counter NSAIDS or vitamins could not be accounted for 
due to the nature of Medicaid prescription claims data.   
The results of this study point to an effective point of intervention before 14 
months for ET initiators who meet the sample inclusion criteria and that ET type and 
other prescriptions taken by survivors are more important for increasing the length of ET 
duration than the demographic and clinical factors examined.  Further research is 
warranted to test these findings in other populations. Further research is also needed to 
test pharmacologic intervention strategies associated with longer ET duration in this 
study in addition to other non-pharmacologic interventions among low income 
populations (David & Fallowfield, 2008).  
The knowledge gained from the focus groups is critical to guide future 
development of interventions aimed at increasing ET continuation in this population. 
Most notably, researchers and clinicians must consider how to address survivor concerns 
regarding a more open, honest, ongoing two-way discussion between survivors and their 
providers. Consistent with other studies of breast cancer survivors’ preferences, our study 
showed that it may be helpful to employ a shared decision making model as the standard 
of care when approaching the concept of endocrine therapy continuation and 
modification of breast cancer recurrence risk factors, as is already being implemented for 
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initial breast cancer diagnosis and treatment (Mahmoodi & Sargeant, 2017; Mandelblatt 
et al., 2006; Charles, Gafni, & Whelan, 2004).  
Survivors expressed a strong desire to make their own decisions with information 
and guidance from their providers, consistent with the findings of Wells et al. (2016). 
Some survivors indicated they were not able to have honest conversations about ET with 
their providers. Others alluded to feeling condemned when trying to raise the issue of 
side effects or information found online or from other women. In order for a shared 
decision making model to be implemented more effectively, it may be useful to train 
breast cancer survivors to more assertively communicate with their providers, as has been 
effective with other patient populations (Lee et al., 2013). Likewise, the principles and 
practice of shared decision-making should continually be incorporated in medical 
education and oncology residency training programs.  
Another main topic in patient/provider communication centered on discussions of 
patient information seeking. Our study showed that survivors whose doctors criticized or 
dismissed the online information they presented were more likely to follow advice from 
other sources or go against the doctor’s advice possibly due to this perceived dissonance. 
Tan and Goonawardene (2017) conducted a systematic review of Internet Health 
Information Seeking and the Patient-Physician Relationship. Similar to accounts reported 
by some of the survivors in our study, this systematic review showed that some survivors 
felt physicians avoided online information-related dialogues in order to reclaim the 
traditional, authoritarian consultation model. Tan and Goonawardene affirm the 
importance of allowing or encouraging survivors to discuss their online information 
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searches with physicians. Their findings showed that survivors mainly used the internet 
to be actively involved in decision making related to their health (i.e. preparing for visits, 
asking better questions, better understanding information from physicians) but still very 
much trusted their physicians and valued their consultations. This finding offers a 
specific opportunity to provide patient centered care: provider’s recognition of a patient’s 
efforts in the self-education process. 
The utility of multidisciplinary oncology teams that can incorporate integrative 
approaches was highlighted in the focus groups. Some survivors had benefitted from care 
by such teams while others had not. Multidisciplinary cancer care can be defined as a 
“deliberately designed system that creates a common communication platform among 
different providers of cancer care, enabling complex decision making and resulting in a 
tailored individual management plan” (Jacobson, 2010). The need for multidisciplinary 
care arose from survivors feeling overwhelmed and confused after being transferred 
between clinicians at various stages of diagnosis and treatment without an integrated 
approach (Jnr, 2011). While existing multidisciplinary teams may typically be physician-
led, our study shows that it may be helpful to also include allied health professionals such 
as pharmacists, nurse navigators, and nutritionists who may be working directly with the 
patient over the course of five to ten years and can provide more individual counsel and 
information related to integrative approaches as survivors continually re-evaluate the 
decision of whether to continue ET (Taplin et al., 2016). Incorporating these individuals 
as part of the care team may also help improve the continuity of care, especially 
throughout the cancer survivorship journey. Multidisciplinary teams that include allied 
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health professionals and nurse navigators align with the transition to a more patient-
centered approach in cancer care, in which increasing emphasis is placed on a survivor’s 
overall well-being and quality of life, and survivorship (Borras et al., 2014; Lee 
Mortensen et al., 2017). 
As breast cancer survivors become an increasingly larger population, there is 
imminent need for novel patient-centered interventions to enhance the ET experience. 
This research and other patient-centered approaches are increasingly valuable in 
providing insight into survivor care needs and perceptions, with a goal of ensuring that 
cancer survivors have an opportunity for the most comprehensive and highest quality 
cancer care possible. Interventions aimed at enhancing the ET experience for breast 
cancer survivors to increase disease free survival and quality of life are an immediate 
need. The results of this study can be seen as an important first step at examining factors 
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Table of Variables 
Variables Data Source Research Question 
QUANTITATIVE STUDY 
Sex, age at diagnosis, SEER summary breast 
cancer stage, month/year of diagnosis 
SC Central Cancer 
Registry 
Inclusion/exclusion 
criteria; #1, #2, #3 
Cancer recurrence date, type of reporting 
source (to distinguish autopsy or death 
certificate), vital status 




Dual enrollment in Medicare  Inclusion/exclusion 
criteria 
National Drug Code and drug name, date 
dispensed 
SC Medicaid Pharmacy 
File 
Inclusion/exclusion 
criteria, #1, #2, #3 
Medicaid eligibility & ineligibility dates SC Medicaid Recipient 
File 
#1, #2, #3 
Quantity, number of this refill & days 
supplied 
SC Medicaid Pharmacy 
File 
#1, #2, #3 
Demographic: race SC Central Cancer 
Registry 
#1 & #3 
Demographic: rural/urban residency status, 
county of residence, marital status 
SC Central Cancer 
Registry 
#3 
Demographic: marital status SC Medicaid Recipient 
File 
#3 
Clinical: receipt of other treatments (i.e. 
chemotherapy, radiation therapy, surgery) 
SC Central Cancer 
Registry 
#3 
Pharmaceutical: type of endocrine therapy, 
pharmacy ownership, and filled prescription 
for the following - alpha-agonist 
hypertensives, antidepressants, 
anticonvulsants, adrenals, nonsteroidal anti-
inflammatory agents, anti-inflammatory 
agents, and/or vitamins (B, C, D, K, and/or 
multivitamin) 




Perceived susceptibility to and 
seriousness/severity of breast cancer 
recurrence 
Focus groups #4 
Perceived benefits of and barriers to 
endocrine therapy continuation and adherence 
Focus groups #5 
Cues to action that encourage and support ET 
continuation and adherence 









Hello, (name). Are you calling about the breast cancer study? 
 
Thank you for calling and for your interest in this study. My name is Julie, and I am a 
research assistant at Clemson University. How are you today? 
 
We understand that it is a challenge for many women to complete therapy for breast 
cancer. We would like to talk to you to find out more about your experience so that we 
can help other women in the future. To learn more about your experience, we would like 
to schedule a time when you and five or six other women could come and meet together 
with us to talk about your experiences.  
 
First, I need to ask you several questions to see if you might qualify for our focus group.  
Is that okay? 
 
We will have three different groups that meet, so to determine which group you best fit 
in, may I ask you a few questions? 
 Were you ever prescribed Tamoxifen?  
o If don’t know, ask:  Were you ever given a prescription by your doctor 
after they completed their initial treatment?   
 Do you remember what it was for?  (If say, to reduce estrogen or 
hormones in the body, then assume Tamoxifen or AI) 
 Were you ever prescribed an aromatase inhibitor?  
o Probe; (If they don’t know, then list all and ask one by one, e.g. 
Anastrozole/Arimidex, letrozole/Femara, or Exemestane/Aromasin?) 
 
<<IF YES, continue with following questions.  IF NO, then skip to Option 2, 
below…>> 
 Did you ever fill your prescription for Tamoxifen (or AI)? 
 If yes, for how long did you take Tamoxifen (or AI)? 
 Do you remember how old you were when you were first prescribed 
Tamoxifen/aromatase inhibitor? 
 Are you a female?   
 What stage of breast cancer were you diagnosed with? 
 
Eligibility criteria:  
 Either prescribed Tamoxifen and/or an aromatase inhibitor: yes 
 Female: yes 
 Age when began taking Tamoxifen/aromatase inhibitor: 18-64 
 English speaker: yes 
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 Completed treatment for hormone receptor-positive breast cancer: yes 
 
Option 1 (if eligible to participate in study): Thank you so much for these responses. 
(Provide details of appropriate focus group – date, time, and location.) In case something 
comes up and you will be unable to attend the focus group, will you please call or text me 
at (864)270-3259? Also, to remind you about the event and to send you any updates, may 
I ask for your name, phone number, and e-mail address? How would you prefer that I be 
in contact with you? Thank you again for your interest and for your willingness to 
participate. We hope that our conversation and the information we learn from your 
experience can be used to help many other women. At the end of our focus group, we 
will be giving you a $50 Walmart gift card to thank you for your time. Do you have any 
questions about the focus group? Thank you again for your interest. Have a nice day. 
 
Option 2 (if not eligible to participate in study): Thank you so much for these responses. 
Unfortunately, you do not meet the eligibility criteria for our study, so I will not be able 
to schedule you to participate in a focus group. (Explain why.) Thank you again for your 




Focus Group Guide 
WELCOME  
Thank you so much for agreeing to be part of this focus group. We appreciate your 
willingness to participate and look forward to a fruitful discussion together.  
 
Today, we are talking with women who are breast cancer survivors, and we are interested 
in learning more about your experience. 
INTRODUCTIONS  
Moderator; assistant moderator  
 
PURPOSE OF FOCUS GROUPS  
The reason we are having these focus groups is that it is a challenge for many women to 
complete endocrine therapy for breast cancer. When we say endocrine therapy, we are 
referring to either Tamoxifen or an Aromatase Inhibitor, medications you may have taken 
after your surgery, chemotherapy, radiation, or any other kind of treatment.  We want to 
find out more about the obstacles that you and other women you know have faced in 
order to better aid women in the future. We need your input and want you to share your 
honest and open thoughts with us. This focus group will last approximately 1 ½ hours. 
Please feel free to get up to go to the restroom anytime. At the end of our time together, 
please see [assistant moderator] to receive your $50 Wal-Mart gift card as we value and 
appreciate your time today. 
 
GROUND RULES  
 
We would like to address a few important points before we begin. 
 
1. WE WANT YOU TO DO THE TALKING.  
We would like for everyone to participate.  
We value each of you and your responses. If you have shared a lot, I may call on others 
who we haven't heard from in a while so that everyone can have a chance to share. 
 
2. THERE ARE NO RIGHT OR WRONG ANSWERS  
Every person's experiences and opinions are important.  
Please feel free to speak up whether you agree or disagree.  
We want to hear a wide range of opinions.  
 
3. WHAT IS SAID IN THIS ROOM STAYS HERE  
We want folks to feel comfortable sharing when sensitive issues come up.  
 
4. WE WILL BE AUDIO RECORDING THE GROUP  
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We want to capture everything you have to say.  
We absolutely will not identify anyone by name in our report. You will remain 
anonymous. If we use your words we will simply say “one participant told us” – we will 
not use your name or describe you in a way that someone could identify you. 
 
So, if you are ready, we will get started with the recording. 
 
Patient introductions/Icebreaker: Please tell us you’re the name that you would like for 
us to call you as well as how long ago you were diagnosed with breast cancer.  
 
We understand that you have all had different types of breast cancer treatments, possibly 
involving chemotherapy, radiation therapy, or surgery, but we want to spend the rest of 
our time together today discussing what happened after these initial treatments.  
After your chemo, radiation, or surgery, how many of you received a prescription for 
Tamoxifen?  
Did anyone receive a prescription for an aromatase inhibitor like Anastrozole/Arimidex, 
letrozole/Femara, or Exemestane/Aromasin? Or any other medication? 
Did anyone switch from one medication to another? (Probe as to why the switch from one 
to the other. What did the new drug do instead?) 
Do you remember what type of doctor wrote that first prescription? (Was it your surgeon 
or oncologist or a different type of doctor?) During the remainder of our conversation, I 
may use the word “provider” when I talk about the doctor since your medical visits may 
have been with a doctor, a nurse, a nurse practitioner, or some other healthcare 
professional.  
Perceived Benefits/Barriers: We understand that when you are finishing up cancer 
treatment, you may have lots of different appointments with several different doctors and 
that there is a lot of information to take in and decisions to make…We would like for you 
to think back if possible to that time when you had finished your chemo, radiation, and/or 
surgery and were given the option to take Tamoxifen or an aromatase inhibitor. Tell us 
about your experience of going to the doctor and receiving your first prescription. For 
example, we would like to hear what you and your doctors discussed, if more than one 
doctor talked to you about taking the medication and what those conversations were like, 
if you took someone with you to those appointments and what their role was, how you 
felt during those appointments, etc. 
How often did your doctor say you would need to take the medication each day (whole 
pills?), and for how long would you be on the medication? 
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(What did you and your providers discuss? Encouraged to fill the prescription and take 
the medicine? Comfortable asking questions? Same/different messages from each 
provider? Role of the “advocate”?)  
Perceived Susceptibility/Seriousness/Severity: At that point when you were first given 
your Tamoxifen or aromatase inhibitor prescription, how much did worry about cancer 
coming back influence your decision of whether or not to fill the prescription?  
We know that all of you did decide to fill your first prescription and took either 
Tamoxifen or an aromatase inhibitor, and we want to hear more about your decision 
making process. Can you tell us just in your own words more about the benefits you saw 
in taking this medication – for example, the purpose of the medication and how you 
learned about it?  
 
We know that all of you decided to take the medicine. Can you elaborate more for 
us on your experience with taking it - how easy or how difficult if may have been, 
and how it impacted your way of life, if at all? 
 
It is a challenge for many women to continue taking their medicine for breast cancer for 
a variety of reasons. Based on your own experience or things you have heard from other 
women, we would like to brainstorm together why it can be very challenging for women 
to take their medicine regularly and stay on it for the duration the doctor recommends. 
Ask women to brainstorm.  
 
Prompts if needed:  
 Side effects – please describe 
 Cost/difficulty getting medicine refilled 
 Feeling good so why continue, in denial/want to forget about cancer 
 Conflicting advice from doctors/internet/other women 
 Sexual problems/fertility concerns 
 Developing other health problems or the fear of developing other health 
problems 
 Can’t avail support services due to work  
 Misunderstanding from family/physicians 
 Distance from care 
 
We would like to learn more about how it feels talking with your provider about your 
medication and any challenges you may have experienced. (Did you wait til you had an 
appointment to share your concerns, or did you call ahead of time? Did you feel that 
your provider was open to listening to you and to helping you find a way to alleviate 
some of the problems you were experiencing? Did you ever feel embarrassed to talk to 
the doctor about your concerns? If you decided to stop taking the medicine, did you and 
your provider make that decision together or did you make that decision on your own?)  
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Next, we want to ask specifically about your experience in getting the Tamoxifen or 
aromatase inhibitors with regard to the cost, insurance coverage, and convenience to the 
pharmacy, etc. 
Please tell us about your experience in getting the medicines with your insurance 
coverage. (Any difficulties obtaining the medicines? Any gaps or problems with your 
insurance coverage? Did your insurance cover the full expense of your medication? Is 
there anything about your experience with your insurance that could have better 
supported you if you wanted to stay on the medicine?) 
 
Cues to Action:  
We would like to know what suggestions you have that would be helpful to women who 
are prescribed these medications and decide to take them daily for the entire duration 
needed. If you chose to take the medicine, while you were taking it, what are some things 
that were helpful to you? If you did not take the medicine, can you think of anything that 
may would be helpful to others? (Things to know before you began taking your 
medication, or to help you continue taking your medication? Examples of tried 
interventions below if needed.)  
 
 Educational pamphlets in the mail (topics: breast cancer, treatments, medication 
side effects, strategies for enhancing adherence, and information about diet and 
physical exercise) 
 Monthly reminders in the mail or by e-mail about medication adherence 
 Phone calls from a nurse to provide motivation, reminders, and individualized 
information regarding the patient’s specific problems 
 Text messaging app that allows the patient to text the provider 
 Group exercise programs 
 At home-based exercise programs 
 Cool pad pillow topper to aid sleep 
 Meditation training to decrease stress/anxiety 
 
We are getting close to the end of our discussion time.  What additional thoughts would 
you like to share with the group about your experience with endocrine therapy or any 
experiences of other people you know? 
 










Thank you so much for your willingness to come and participate in the focus group. We 
look forward to our time together and trust that the experiences and ideas you share can 
be used to help many women in the future. Below are some short survey questions to give 
us a better idea about your history with endocrine therapy. 
 
1. Were you diagnosed with hormone receptor-positive breast cancer?  YES        
NO 
 
 If yes, what year were you diagnosed?  ____________________________ 
 
 What was your stage at diagnosis?  
 Stage 0   Stage I   Stage II   Stage III   Stage IV 
 
2. Have you completed your breast cancer treatment?  YES        NO 
 
 If yes, what year did you complete your treatment? __________________ 
 
3. Were you ever prescribed Tamoxifen?   YES        NO 
 
 If yes, did you fill your prescription for Tamoxifen?  YES        NO 
 
 If yes, how long did you take Tamoxifen? ____________________________ 
 
 
4. Were you ever prescribed an aromatase inhibitor? (Aromatase inhibitors include 
the following medications: Anastrozole/Arimidex, Letrozole/Femara, or 
Exemestane/Aromasin.)   YES   NO 
 
 If yes, did you fill your prescription for an aromatase inhibitor?  YES  NO 
 If yes, how long did you take the aromatase inhibitor? ___________________ 
 
5. How old were you when you were first prescribed Tamoxifen or an aromatase 
inhibitor? ________ 
 
6. What type of insurance did you have while taking Tamoxifen or an aromatase 
inhibitor? _________________________________________________________ 
 
7. What is your race? __________________________________________________ 
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8. Education received:  
              Some High School          High School Graduate or GED       
  Associates Degree           Bachelor’s Degree          Masters or Doctorate        
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